1
|
Sinikumpu S, Huilaja L, Jokalainen J, Auvinen J, Puukka K, Ruokonen A, Timonen M, Tasanen K. 510 The association between low grade inflammation and skin diseases. A cross-sectional survey in the Northern Finland Birth Cohort 1966. J Invest Dermatol 2017. [DOI: 10.1016/j.jid.2017.07.706] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
2
|
Ollila MM, West S, Keinänen-Kiukaaniemi S, Jokelainen J, Auvinen J, Puukka K, Ruokonen A, Järvelin MR, Tapanainen JS, Franks S, Piltonen TT, Morin-Papunen LC. Overweight and obese but not normal weight women with PCOS are at increased risk of Type 2 diabetes mellitus-a prospective population-based cohort study. Hum Reprod 2017; 32:968. [PMID: 28333219 DOI: 10.1093/humrep/dex030] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- M M Ollila
- Department of Obstetrics and Gynaecology, Oulu University Hospital, University of Oulu, Medical Research Center Oulu and PEDEGO Research Unit, FI, OYS, Oulu, Finland
| | - S West
- Department of Obstetrics and Gynaecology, Oulu University Hospital, University of Oulu, Medical Research Center Oulu and PEDEGO Research Unit, FI, OYS, Oulu, Finland
| | - S Keinänen-Kiukaaniemi
- Center for Life Course Health Research, University of Oulu, FI, Oulu, Finland.,Unit of Primary Health Care, Oulu University Hospital, FI, Oulu, Finland
| | - J Jokelainen
- Center for Life Course Health Research, University of Oulu, FI, Oulu, Finland.,Unit of Primary Health Care, Oulu University Hospital, FI, Oulu, Finland
| | - J Auvinen
- Center for Life Course Health Research, University of Oulu, FI, Oulu, Finland.,Unit of Primary Health Care, Oulu University Hospital, FI, Oulu, Finland
| | - K Puukka
- NordLab Oulu, Department of Clinical Chemistry, Oulu University Hospital, University of Oulu and Medical Research Center, FI, Oulu, Finland
| | - A Ruokonen
- NordLab Oulu, Department of Clinical Chemistry, Oulu University Hospital, University of Oulu and Medical Research Center, FI, Oulu, Finland
| | - M-R Järvelin
- Center for Life Course Health Research, University of Oulu, FI, Oulu, Finland.,Department of Children, Young People and Families, National Institute for Health and Welfare, FI, Oulu, Finland.,Department of Epidemiology and Biostatistics, MRC-PHE Centre for Environment & Health, School of Public Health, Imperial College London,London, UK
| | - J S Tapanainen
- Department of Obstetrics and Gynaecology, Oulu University Hospital, University of Oulu, Medical Research Center Oulu and PEDEGO Research Unit, FI, OYS, Oulu, Finland.,Department of Obstetrics and Gynaecology, University of Helsinki and Helsinki University Hospital, FI, Helsinki, Finland
| | - S Franks
- Institute of Reproductive and Developmental Biology, Imperial College London, Hammersmith Hospital, London, UK
| | - T T Piltonen
- Department of Obstetrics and Gynaecology, Oulu University Hospital, University of Oulu, Medical Research Center Oulu and PEDEGO Research Unit, FI, OYS, Oulu, Finland
| | - L C Morin-Papunen
- Department of Obstetrics and Gynaecology, Oulu University Hospital, University of Oulu, Medical Research Center Oulu and PEDEGO Research Unit, FI, OYS, Oulu, Finland
| |
Collapse
|
3
|
Ollila MM, West S, Keinänen-Kiukaanniemi S, Jokelainen J, Auvinen J, Puukka K, Ruokonen A, Järvelin MR, Tapanainen JS, Franks S, Piltonen TT, Morin-Papunen LC. Overweight and obese but not normal weight women with PCOS are at increased risk of Type 2 diabetes mellitus-a prospective, population-based cohort study. Hum Reprod 2016; 32:423-431. [PMID: 28031324 DOI: 10.1093/humrep/dew329] [Citation(s) in RCA: 88] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2016] [Revised: 11/29/2016] [Accepted: 12/16/2016] [Indexed: 12/15/2022] Open
Abstract
STUDY QUESTION What are the respective roles of polycystic ovary syndrome (PCOS), long-term weight gain and obesity for the development of prediabetes or Type 2 diabetes mellitus (T2DM) by age 46 years? SUMMARY ANSWER The risk of T2DM in women with PCOS is mainly due to overweight and obesity, although these two factors have a synergistic effect on the development of T2DM. WHAT IS KNOWN ALREADY PCOS is associated with an increased risk of prediabetes and T2DM. However, the respective roles of PCOS per se and BMI for the development of T2DM have remained unclear. STUDY DESIGN, SIZE, DURATION In a prospective, general population-based follow-up birth cohort 1966 (n = 5889), postal questionnaires were sent at ages 14 (95% answered), 31 (80% answered) and 46 years (72% answered). Questions about oligoamenorrhoea and hirsutism were asked at age 31 years, and a question about PCOS diagnosis at 46 years. Clinical examination and blood sampling were performed at 31 years in 3127 women, and at 46 years in 3280 women. A 2-h oral glucose tolerance test (OGTT) was performed at 46 years of age in 2780 women. PARTICIPANTS/MATERIALS, SETTING, METHODS Women reporting both oligoamenorrhoea and hirsutism at age 31 years and/or diagnosis of PCOS by 46 years were considered as women with PCOS (n = 279). Women without any symptoms at 31 years and without PCOS diagnosis by 46 years were considered as controls (n = 1577). The level of glucose metabolism was classified according to the results of the OGTT and previous information of glucose metabolism status from the national drug and hospital discharge registers. MAIN RESULTS AND THE ROLE OF CHANCE PCOS per se significantly increased the risk of T2DM in overweight/obese (BMI ≥ 25.0 kg/m2) women with PCOS when compared to overweight/obese controls (odds ratio: 2.45, 95% CI: 1.28-4.67). Normal weight women with PCOS did not present with an increased risk of prediabetes or T2DM. The increase in weight between ages 14, 31 and 46 years was significantly greater in women with PCOS developing T2DM than in women with PCOS and normal glucose tolerance, with the most significant increase occurring in early adulthood (between 14 and 31 years: median with [25%; 75% quartiles]: 27.25 kg [20.43; 34.78] versus 13.80 kg [8.55; 20.20], P < 0.001). LIMITATIONS, REASONS FOR CAUTION The diagnosis of PCOS was based on self-reporting, and the questionnaire at 46 years did not distinguish between polycystic ovaries only in ultrasonography and the syndrome. Ovarian ultrasonography was not available to aid the diagnosis of PCOS. WIDER IMPLICATIONS OF THE FINDINGS These results emphasize weight management already during adolescence and early adulthood to prevent the development of T2DM in women with PCOS, as the period between 14 and 31 years seems to be a crucial time-window during which the women with PCOS who are destined to develop T2DM by 46 years of age experience a dramatic weight gain. Furthermore, our results support the view that, particularly in times of limited sources of healthcare systems, OGTT screening should be targeted to overweight/obese women with PCOS rather than to all women with PCOS. STUDY FUNDING/COMPETING INTERESTS Finnish Medical Foundation; North Ostrobothnia Regional Fund; Academy of Finland (project grants 104781, 120315, 129269, 1114194, 24300796, Center of Excellence in Complex Disease Genetics and SALVE); Sigrid Juselius Foundation; Biocenter Oulu; University Hospital Oulu and University of Oulu (75617); Medical Research Center Oulu; National Institute for Health Research (UK); National Heart, Lung, and Blood Institute (grant 5R01HL087679-02) through the STAMPEED program (1RL1MH083268-01); National Institute of Health/National Institute of Mental Health (5R01MH63706:02); ENGAGE project and grant agreement HEALTH-F4-2007-201413; EU FP7 EurHEALTHAgeing-277849 European Commission and Medical Research Council, UK (G0500539, G0600705, G1002319, PrevMetSyn/SALVE) and Medical Research Center, Centenary Early Career Award. The authors have no conflicts of interests. TRIAL REGISTRATION NUMBER N/A.
Collapse
Affiliation(s)
- M M Ollila
- Department of Obstetrics and Gynaecology, Oulu University Hospital, University of Oulu, Medical Research Center Oulu and PEDEGO Research Unit, FI-90029, OYS, Oulu, Finland
| | - S West
- Department of Obstetrics and Gynaecology, Oulu University Hospital, University of Oulu, Medical Research Center Oulu and PEDEGO Research Unit, FI-90029, OYS, Oulu, Finland
| | - S Keinänen-Kiukaanniemi
- Center for Life Course Health Research, University of Oulu, FI-90014, Oulu, Finland.,Unit of Primary Health Care, Oulu University Hospital, FI-90220, Oulu, Finland
| | - J Jokelainen
- Center for Life Course Health Research, University of Oulu, FI-90014, Oulu, Finland.,Unit of Primary Health Care, Oulu University Hospital, FI-90220, Oulu, Finland
| | - J Auvinen
- Center for Life Course Health Research, University of Oulu, FI-90014, Oulu, Finland.,Unit of Primary Health Care, Oulu University Hospital, FI-90220, Oulu, Finland
| | - K Puukka
- NordLab Oulu, Department of Clinical Chemistry, Oulu University Hospital, University of Oulu and Medical Research Center Oulu, FI-90220, Oulu, Finland
| | - A Ruokonen
- NordLab Oulu, Department of Clinical Chemistry, Oulu University Hospital, University of Oulu and Medical Research Center Oulu, FI-90220, Oulu, Finland
| | - M-R Järvelin
- Center for Life Course Health Research, University of Oulu, FI-90014, Oulu, Finland.,Department of Children, Young People and Families, National Institute for Health and Welfare, FI-90101, Oulu, Finland.,Department of Epidemiology and Biostatistics, MRC-PHE Centre for Environment & Health, School of Public Health, Imperial College London, W2 1PG, London, UK
| | - J S Tapanainen
- Department of Obstetrics and Gynaecology, Oulu University Hospital, University of Oulu, Medical Research Center Oulu and PEDEGO Research Unit, FI-90029, OYS, Oulu, Finland.,Department of Obstetrics and Gynaecology, University of Helsinki and Helsinki University Hospital, FI-00014, Helsinki, Finland
| | - S Franks
- Institute of Reproductive and Developmental Biology, Imperial College London, Hammersmith Hospital, W12 0NN, London, UK
| | - T T Piltonen
- Department of Obstetrics and Gynaecology, Oulu University Hospital, University of Oulu, Medical Research Center Oulu and PEDEGO Research Unit, FI-90029, OYS, Oulu, Finland
| | - L C Morin-Papunen
- Department of Obstetrics and Gynaecology, Oulu University Hospital, University of Oulu, Medical Research Center Oulu and PEDEGO Research Unit, FI-90029, OYS, Oulu, Finland
| |
Collapse
|
4
|
Jarvela IY, Pelkonen S, Uimari O, Makikallio K, Puukka K, Ruokonen A, Tekay A, Martikainen H. Controlled ovarian hyperstimulation leads to high progesterone and estradiol levels during early pregnancy. Hum Reprod 2014; 29:2393-401. [DOI: 10.1093/humrep/deu223] [Citation(s) in RCA: 37] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023] Open
|
5
|
West S, Lashen H, Bloigu A, Franks S, Puukka K, Ruokonen A, Järvelin MR, Tapanainen JS, Morin-Papunen L. Irregular menstruation and hyperandrogenaemia in adolescence are associated with polycystic ovary syndrome and infertility in later life: Northern Finland Birth Cohort 1986 study. Hum Reprod 2014; 29:2339-51. [PMID: 25085801 DOI: 10.1093/humrep/deu200] [Citation(s) in RCA: 40] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
STUDY QUESTION Do teenage girls with a history of menstrual irregularity and/or elevated androgen levels in adolescence exhibit an increased risk of polycystic ovary syndrome (PCOS) and/or infertility later on in adulthood? SUMMARY ANSWER Our results suggest that menstrual irregularity and/or elevated androgen levels at 16 years are still associated with symptoms of PCOS at 26 years as well as infertility problems at 26 years but not with decreased pregnancy or delivery rates at 26 years. WHAT IS KNOWN ALREADY Hyperandrogenaemia is associated with menstrual irregularity, hirsutism, acne and potentially higher risk for PCOS, but there are few follow-up studies investigating whether adolescent hyperandrogenaemia and/or menstrual irregularity are an early sign of PCOS. STUDY DESIGN, SIZE, DURATION A prospective population-based cohort study was conducted using two postal questionnaires targeting girls in the Northern Finland Birth Cohort 1986 (NFBC1986, n = 4567). The NFBC1986 comprises all expected births from the year 1986 in the two northernmost provinces of Finland. Collection of the database was performed at the age of 16 and 26. The 16-year and 26-year questionnaires included one question about the regularity and length of the menstrual cycle. The 26-year questionnaire also included questions about symptoms of PCOS, reproduction and infertility problems. PARTICIPANTS, SETTING, METHODS The response rates for the questionnaires were 80% (n = 3669) at 16 years and 50% (n = 2270) at 26 years. At 15-16 years, of 2448 girls, 709 (29%) girls reported menstrual irregularity (symptomatic girls) and 1739 (71%) had regular periods (non-symptomatic girls). After combining data from the two questionnaires a total of 2033 girls were included in the analyses. The χ(2) and Student's t-test was used to compare reproductive outcome and prevalence of clinical hyperandrogenaemia, PCOS and infertility at 26 years between the study groups. Univariate and multivariate logistic regression models were employed to estimate the association of menstrual irregularity at 16 years with clinical hyperandrogenaemia, PCOS and infertility at 26 years. MAIN RESULTS AND THE ROLE OF CHANCE At follow-up, the proportion of symptomatic girls who had conceived at least once (68.0 versus 67.9%) and had delivered at least one child (25.7 versus 28.1%) was similar to the non-symptomatic women and the groups had similar miscarriage rates (11.6 versus 12.1%). Logistic regression analyses indicated that menstrual irregularity at 16 years was associated with an increased risk of menstrual irregularity [adjusted odds ratio (OR) 1.37, 95% confidence interval (CI) 1.00-1.88, P = 0.050], PCOS (adjusted OR 2.91, 95% CI 1.74-4.84, P < 0.001) and infertility problems (adjusted OR 2.07, 95% CI 1.16-3.76, P = 0.013) at 26 years. At 26 years, women with PCOS (P = 0.013), hirsutism (P = 0.001) and acne (P < 0.001) exhibited significantly higher values of free androgen index (FAI) at 16 years than control women. There was a significant linear trend in the higher FAI quartiles at 16 years towards higher prevalence of PCOS (P = 0.005), hirsutism (P < 0.001) and acne (P < 0.001) at 26 years. Only 10.5% of the girls with menstrual irregularity at 16 years had PCOS at 26 years. LIMITATIONS, REASONS FOR CAUTION The diagnosis of menstrual irregularity was based on a self-reported questionnaire, thus introducing a risk of information bias in reporting the symptoms. Moreover, ovarian ultrasonography was not available to aid the diagnosis of PCOS and there was no clinical evaluation of hyperandrogenism. The relatively low rate of participation to the questionnaire at 26 years may also have biased the results. WIDER IMPLICATIONS OF THE FINDINGS Our findings confirm that menstrual irregularity and/or elevated androgen levels are already present in adolescence in women with PCOS and infertility in later life, which strengthens the importance of early identification of menstrual irregularity. STUDY FUNDING/COMPETING INTERESTS This work was supported by grants from the Finnish Medical Society Duodecim, the North Ostrobothnia Regional Fund, the Academy of Finland, the Sigrid Juselius Foundation, University Hospital Oulu and University of Oulu, the European Commission and the Medical Research Council, UK, Welcome Trust (089549/Z/09/Z). None of the authors have any conflict of interest.
Collapse
Affiliation(s)
- S West
- Department of Obstetrics and Gynaecology, University Hospital of Oulu, University of Oulu, Oulu, Finland
| | - H Lashen
- Department of Human Metabolism, University of Sheffield, Jessop Wing, Sheffield S10 2SF, UK
| | - A Bloigu
- Department of Children, Young People and Families, National Institute for Health and Welfare, Oulu, Finland
| | - S Franks
- Institute of Reproductive and Developmental Biology, Imperial College London, London, UK
| | - K Puukka
- NordLab Oulu, Oulu University Hospital and Department of Clinical Chemistry, University of Oulu, Oulu, Finland
| | - A Ruokonen
- NordLab Oulu, Oulu University Hospital and Department of Clinical Chemistry, University of Oulu, Oulu, Finland
| | - M-R Järvelin
- Department of Children, Young People and Families, National Institute for Health and Welfare, Oulu, Finland Department of Epidemiology and Biostatistics, MRC Health Protection Agency (HPA) Centre for Environment and Health, School of Public Health, Imperial College London, London, UK Institute of Health Sciences, University of Oulu, Oulu, Finland Biocenter Oulu, University of Oulu, Oulu, Finland Unit of Primary Care, University Hospital of Oulu, University of Oulu, Oulu, Finland
| | - J S Tapanainen
- Department of Obstetrics and Gynaecology, University Hospital of Oulu, University of Oulu, Oulu, Finland Department of Obstetrics and Gynaecology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland
| | - L Morin-Papunen
- Department of Obstetrics and Gynaecology, University Hospital of Oulu, University of Oulu, Oulu, Finland
| |
Collapse
|
6
|
Pinola P, Morin-Papunen LC, Bloigu A, Puukka K, Ruokonen A, Järvelin MR, Franks S, Tapanainen JS, Lashen H. Anti-Müllerian hormone: correlation with testosterone and oligo- or amenorrhoea in female adolescence in a population-based cohort study. Hum Reprod 2014; 29:2317-25. [PMID: 25056088 PMCID: PMC4164146 DOI: 10.1093/humrep/deu182] [Citation(s) in RCA: 32] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022] Open
Abstract
STUDY QUESTIONS Can serum anti-Müllerian hormone (AMH) levels measured in female adolescents predict polycystic ovary syndrome (PCOS)-associated features in adolescence and early adulthood? SUMMARY ANSWER AMH levels associated well with PCOS-associated features (such as testosterone levels and oligoamenorrhoea) in adolescence, but was not an ideal marker to predict PCOS-associated features in early adulthood. WHAT IS KNOWN ALREADY Several studies have reported that there is a strong correlation between antral follicle count and serum AMH levels and that women with PCOS/PCO have significantly higher serum AMH levels than women with normal ovaries. Other studies have reported an association between AMH serum levels and hyperandrogenism in adolescence, but none has prospectively assessed AMH as a risk predictor for developing features of PCOS during adulthood. STUDY DESIGN, SIZE, DURATION A subset of 400 girls was selected from the prospective population-based Northern Finland Birth Cohort 1986 (n = 4567 at age 16 and n = 4503 at age 26). The population has been followed from 1986 to the present. PARTICIPANTS/MATERIAL, SETTING, METHODS At age 16, 400 girls (100 from each testosterone quartile: 50 with oligo- or amenorrhoea and 50 with a normal menstrual cycle) were selected at random from the cohort for AMH measurement. Metabolic parameters were also assessed at age 16 in all participants. Postal questionnaires enquired about oligo- or amenorrhoea, hirsutism, contraceptive use and reproductive health at ages 16 and 26. MAIN RESULTS AND ROLE OF CHANCE There was a significant correlation between AMH and testosterone at age 16 (r = 0.36, P < 0.001). AMH levels at age 16 were significantly higher among girls with oligo- or amenorrhoea compared with girls with normal menstrual cycles (35.9 pmol/l [95% CI: 33.2;38.6] versus 27.7 pmol/l [95% CI: 25.0;30.4], P < 0.001). AMH at age 16 was higher in girls who developed hirsutism at age 26 compared with the non-hirsute group (31.4 pmol/l [95% CI 27.1;36.5] versus 25.8 pmol/l [95% CI 23.3;28.6], P = 0.036). AMH at age 16 was also higher in women with PCOS at age 26 compared with the non-PCOS subjects (38.1 pmol/l [95% CI 29.1;48.4] versus 30.2 pmol/l [95% CI 27.9;32.4], P = 0.044). The sensitivity and specificity of the AMH (cut-off 22.5 pmol/l) for predicting PCOS at age 26 was 85.7 and 37.5%, respectively. The addition of testosterone did not significantly improve the accuracy of the test. There was no significant correlation between AMH levels and metabolic indices at age 16. IMPLICATIONS, REASONS FOR CAUTION AMH is related to oligo- or amenorrhoea in adolescence, but it is not a good marker for metabolic factors. The relatively low rate of participation in the questionnaire at age 26 may also have affected the results. AMH was measured in a subset of the whole cohort. AMH measurement is lacking international standardization and therefore the concentrations and cut-off points are method dependent. WIDER IMPLICATIONS FOR THE FINDINGS Using a high enough cut-off value of AMH to predict which adolescents are likely to develop PCOS in adulthood could help to manage the condition from an early age due to a good sensitivity. However, because of its low specificity, it is not an ideal diagnostic marker, and its routine use in clinical practice cannot, at present, be recommended. STUDY FUNDINGS AND COMPETING INTERESTS The study was funded by a grant from Wellcome Trust (089549/Z/09/Z) to H.L., S.F. and M.-R.J. Study funding was also received from Oulu University Hospital Research Funds, Sigrid Juselius Foundation and the Academy of Finland. None of the authors have any competing interest to declare.
Collapse
Affiliation(s)
- P Pinola
- Department of Obstetrics and Gynaecology, Oulu University Hospital, University of Oulu and Medical Research Center Oulu, Oulu, Finland
| | - L C Morin-Papunen
- Department of Obstetrics and Gynaecology, Oulu University Hospital, University of Oulu and Medical Research Center Oulu, Oulu, Finland
| | - A Bloigu
- Department of Children and Young People and Families, National Institute for Health and Welfare, Aapistie 1, Box 310, FI-90101 Oulu, Finland
| | - K Puukka
- NordLab Oulu, Oulu University Hospital and Department of Clinical Chemistry, University of Oulu, Oulu, Finland
| | - A Ruokonen
- NordLab Oulu, Oulu University Hospital and Department of Clinical Chemistry, University of Oulu, Oulu, Finland
| | - M-R Järvelin
- Department of Children and Young People and Families, National Institute for Health and Welfare, Aapistie 1, Box 310, FI-90101 Oulu, Finland Department of Epidemiology and Biostatistics, MRC Health Protection Agency (HPA) Centre for Environment and Health, School of Public Health, Imperial College London, London, UK Institute of Health Sciences, University of Oulu, PO Box 5000, FI-90014 Oulu, Finland Biocenter Oulu, University of Oulu, Aapistie 5A, PO Box 5000, FI-90014 Oulu, Finland Unit of Primary Care, Oulu University Hospital, Kajaanintie 50, PO Box 20, FI-90220 Oulu, 90029 OYS, Finland
| | - S Franks
- Institute of Reproductive and Developmental Biology, Imperial College London, London, UK
| | - J S Tapanainen
- Department of Obstetrics and Gynaecology, Oulu University Hospital, University of Oulu and Medical Research Center Oulu, Oulu, Finland Department of Obstetrics and Gynaecology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland
| | - H Lashen
- Department of Human Metabolism, University of Sheffield, Jessop Wing, Sheffield, UK
| |
Collapse
|
7
|
Canoy D, Barber TM, Pouta A, Hartikainen AL, McCarthy MI, Franks S, Järvelin MR, Tapanainen JS, Ruokonen A, Huhtaniemi IT, Martikainen H. Serum sex hormone-binding globulin and testosterone in relation to cardiovascular disease risk factors in young men: a population-based study. Eur J Endocrinol 2014; 170:863-72. [PMID: 24670886 DOI: 10.1530/eje-13-1046] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
OBJECTIVE Reduced sex hormone-binding globulin (SHBG) concentration predicts insulin resistance and type 2 diabetes, but its association with cardiovascular disease (CVD) risk is unclear. We examined the association between SHBG and cardiovascular risk factors, independently of total testosterone (TT), in young men. DESIGN Observational, cross-sectional study. SETTING General community. PARTICIPANTS The study included 2716 men aged 31 years in the Northern Finland Birth Cohort in 1996 with clinical examination data and fasting blood samples. OUTCOME VARIABLES Blood pressure (BP), lipids and C-reactive protein (CRP) as biological CVD risk markers. RESULTS SHBG concentration was significantly and inversely related to systolic and diastolic BP, triglycerides and CRP, but positively to HDL cholesterol after adjusting for insulin, BMI, waist circumference, smoking, education and physical activity (all P<0.05). These linearly graded associations persisted with additional adjustment for TT. SHBG was significantly associated with total cholesterol only with adjustment for covariates and TT (P<0.05). The direction and magnitude of associations between TT and risk factors were variable, but further adjustment for insulin, adiposity and SHBG showed positive associations between TT and BP, total and LDL-cholesterol and triglycerides and an inverse association with CRP (all P<0.05), but its relation with HDL-cholesterol was no longer significant. CONCLUSIONS In this cohort of young adult men, higher SHBG concentration was associated with a more favourable CVD risk profile, independently of TT. SHBG concentration modified the associations of TT with CVD risk factors.
Collapse
Affiliation(s)
- D Canoy
- Cancer Epidemiology UnitNuffield Department of Population Health, University of Oxford, Richard Doll Building, Roosevelt Drive, Oxford OX3 7LF, UKDepartment of Metabolic and Vascular HealthWarwick Medical School, University of Warwick, Coventry, UKDepartment of Children and Young People and FamiliesNational Institute for Health and Welfare, Oulu, FinlandDepartment of Obstetrics and GynaecologyOulu University Hospital and University of Oulu, Oulu, FinlandOxford Centre for DiabetesEndocrinology and Metabolism, University of Oxford, Oxford, UKWellcome Trust Centre for Human GeneticsUniversity of Oxford, Oxford, UKDepartment of Surgery and CancerImperial College London, Institute of Reproductive and Developmental Biology, London, UKDepartment of Epidemiology and BiostatisticsImperial College London, MRC-Health Protection Agency Centre for Environment and Health, and School of Public Health, London, UKInstitute of Health SciencesUniversity of Oulu, Oulu, FinlandBiocenter OuluUniversity of Oulu, Oulu, FinlandUnit of Primary CareOulu University Hospital, Oulu, FinlandDepartment of Obstetrics and GynecologyHelsinki University Central Hospital and University of Helsinki, Helsinki, FinlandDepartment of Clinical ChemistryUniversity of Oulu, Oulu, FinlandNorLab OuluOulu University Hospital, Oulu, Finland
| | - T M Barber
- Cancer Epidemiology UnitNuffield Department of Population Health, University of Oxford, Richard Doll Building, Roosevelt Drive, Oxford OX3 7LF, UKDepartment of Metabolic and Vascular HealthWarwick Medical School, University of Warwick, Coventry, UKDepartment of Children and Young People and FamiliesNational Institute for Health and Welfare, Oulu, FinlandDepartment of Obstetrics and GynaecologyOulu University Hospital and University of Oulu, Oulu, FinlandOxford Centre for DiabetesEndocrinology and Metabolism, University of Oxford, Oxford, UKWellcome Trust Centre for Human GeneticsUniversity of Oxford, Oxford, UKDepartment of Surgery and CancerImperial College London, Institute of Reproductive and Developmental Biology, London, UKDepartment of Epidemiology and BiostatisticsImperial College London, MRC-Health Protection Agency Centre for Environment and Health, and School of Public Health, London, UKInstitute of Health SciencesUniversity of Oulu, Oulu, FinlandBiocenter OuluUniversity of Oulu, Oulu, FinlandUnit of Primary CareOulu University Hospital, Oulu, FinlandDepartment of Obstetrics and GynecologyHelsinki University Central Hospital and University of Helsinki, Helsinki, FinlandDepartment of Clinical ChemistryUniversity of Oulu, Oulu, FinlandNorLab OuluOulu University Hospital, Oulu, Finland
| | - A Pouta
- Cancer Epidemiology UnitNuffield Department of Population Health, University of Oxford, Richard Doll Building, Roosevelt Drive, Oxford OX3 7LF, UKDepartment of Metabolic and Vascular HealthWarwick Medical School, University of Warwick, Coventry, UKDepartment of Children and Young People and FamiliesNational Institute for Health and Welfare, Oulu, FinlandDepartment of Obstetrics and GynaecologyOulu University Hospital and University of Oulu, Oulu, FinlandOxford Centre for DiabetesEndocrinology and Metabolism, University of Oxford, Oxford, UKWellcome Trust Centre for Human GeneticsUniversity of Oxford, Oxford, UKDepartment of Surgery and CancerImperial College London, Institute of Reproductive and Developmental Biology, London, UKDepartment of Epidemiology and BiostatisticsImperial College London, MRC-Health Protection Agency Centre for Environment and Health, and School of Public Health, London, UKInstitute of Health SciencesUniversity of Oulu, Oulu, FinlandBiocenter OuluUniversity of Oulu, Oulu, FinlandUnit of Primary CareOulu University Hospital, Oulu, FinlandDepartment of Obstetrics and GynecologyHelsinki University Central Hospital and University of Helsinki, Helsinki, FinlandDepartment of Clinical ChemistryUniversity of Oulu, Oulu, FinlandNorLab OuluOulu University Hospital, Oulu, Finland
| | - A L Hartikainen
- Cancer Epidemiology UnitNuffield Department of Population Health, University of Oxford, Richard Doll Building, Roosevelt Drive, Oxford OX3 7LF, UKDepartment of Metabolic and Vascular HealthWarwick Medical School, University of Warwick, Coventry, UKDepartment of Children and Young People and FamiliesNational Institute for Health and Welfare, Oulu, FinlandDepartment of Obstetrics and GynaecologyOulu University Hospital and University of Oulu, Oulu, FinlandOxford Centre for DiabetesEndocrinology and Metabolism, University of Oxford, Oxford, UKWellcome Trust Centre for Human GeneticsUniversity of Oxford, Oxford, UKDepartment of Surgery and CancerImperial College London, Institute of Reproductive and Developmental Biology, London, UKDepartment of Epidemiology and BiostatisticsImperial College London, MRC-Health Protection Agency Centre for Environment and Health, and School of Public Health, London, UKInstitute of Health SciencesUniversity of Oulu, Oulu, FinlandBiocenter OuluUniversity of Oulu, Oulu, FinlandUnit of Primary CareOulu University Hospital, Oulu, FinlandDepartment of Obstetrics and GynecologyHelsinki University Central Hospital and University of Helsinki, Helsinki, FinlandDepartment of Clinical ChemistryUniversity of Oulu, Oulu, FinlandNorLab OuluOulu University Hospital, Oulu, Finland
| | - M I McCarthy
- Cancer Epidemiology UnitNuffield Department of Population Health, University of Oxford, Richard Doll Building, Roosevelt Drive, Oxford OX3 7LF, UKDepartment of Metabolic and Vascular HealthWarwick Medical School, University of Warwick, Coventry, UKDepartment of Children and Young People and FamiliesNational Institute for Health and Welfare, Oulu, FinlandDepartment of Obstetrics and GynaecologyOulu University Hospital and University of Oulu, Oulu, FinlandOxford Centre for DiabetesEndocrinology and Metabolism, University of Oxford, Oxford, UKWellcome Trust Centre for Human GeneticsUniversity of Oxford, Oxford, UKDepartment of Surgery and CancerImperial College London, Institute of Reproductive and Developmental Biology, London, UKDepartment of Epidemiology and BiostatisticsImperial College London, MRC-Health Protection Agency Centre for Environment and Health, and School of Public Health, London, UKInstitute of Health SciencesUniversity of Oulu, Oulu, FinlandBiocenter OuluUniversity of Oulu, Oulu, FinlandUnit of Primary CareOulu University Hospital, Oulu, FinlandDepartment of Obstetrics and GynecologyHelsinki University Central Hospital and University of Helsinki, Helsinki, FinlandDepartment of Clinical ChemistryUniversity of Oulu, Oulu, FinlandNorLab OuluOulu University Hospital, Oulu, FinlandCancer Epidemiology UnitNuffield Department of Population Health, University of Oxford, Richard Doll Building, Roosevelt Drive, Oxford OX3 7LF, UKDepartment of Metabolic and Vascular HealthWarwick Medical School, University of Warwick, Coventry, UKDepartment of Children and Young People and FamiliesNational Institute for Health and Welfare, Oulu, FinlandDepartment of Obstetrics and GynaecologyOulu University Hospital and University of Oulu, Oulu, FinlandOxford Centre for DiabetesEndocrinology and Metabolism, University of Oxford, Oxford, UKWellcome Trust Centre for Human GeneticsUniversity of Oxford, Oxford, UKDepartment of Surgery and CancerImperial College London, Institute of
| | - S Franks
- Cancer Epidemiology UnitNuffield Department of Population Health, University of Oxford, Richard Doll Building, Roosevelt Drive, Oxford OX3 7LF, UKDepartment of Metabolic and Vascular HealthWarwick Medical School, University of Warwick, Coventry, UKDepartment of Children and Young People and FamiliesNational Institute for Health and Welfare, Oulu, FinlandDepartment of Obstetrics and GynaecologyOulu University Hospital and University of Oulu, Oulu, FinlandOxford Centre for DiabetesEndocrinology and Metabolism, University of Oxford, Oxford, UKWellcome Trust Centre for Human GeneticsUniversity of Oxford, Oxford, UKDepartment of Surgery and CancerImperial College London, Institute of Reproductive and Developmental Biology, London, UKDepartment of Epidemiology and BiostatisticsImperial College London, MRC-Health Protection Agency Centre for Environment and Health, and School of Public Health, London, UKInstitute of Health SciencesUniversity of Oulu, Oulu, FinlandBiocenter OuluUniversity of Oulu, Oulu, FinlandUnit of Primary CareOulu University Hospital, Oulu, FinlandDepartment of Obstetrics and GynecologyHelsinki University Central Hospital and University of Helsinki, Helsinki, FinlandDepartment of Clinical ChemistryUniversity of Oulu, Oulu, FinlandNorLab OuluOulu University Hospital, Oulu, Finland
| | - M R Järvelin
- Cancer Epidemiology UnitNuffield Department of Population Health, University of Oxford, Richard Doll Building, Roosevelt Drive, Oxford OX3 7LF, UKDepartment of Metabolic and Vascular HealthWarwick Medical School, University of Warwick, Coventry, UKDepartment of Children and Young People and FamiliesNational Institute for Health and Welfare, Oulu, FinlandDepartment of Obstetrics and GynaecologyOulu University Hospital and University of Oulu, Oulu, FinlandOxford Centre for DiabetesEndocrinology and Metabolism, University of Oxford, Oxford, UKWellcome Trust Centre for Human GeneticsUniversity of Oxford, Oxford, UKDepartment of Surgery and CancerImperial College London, Institute of Reproductive and Developmental Biology, London, UKDepartment of Epidemiology and BiostatisticsImperial College London, MRC-Health Protection Agency Centre for Environment and Health, and School of Public Health, London, UKInstitute of Health SciencesUniversity of Oulu, Oulu, FinlandBiocenter OuluUniversity of Oulu, Oulu, FinlandUnit of Primary CareOulu University Hospital, Oulu, FinlandDepartment of Obstetrics and GynecologyHelsinki University Central Hospital and University of Helsinki, Helsinki, FinlandDepartment of Clinical ChemistryUniversity of Oulu, Oulu, FinlandNorLab OuluOulu University Hospital, Oulu, FinlandCancer Epidemiology UnitNuffield Department of Population Health, University of Oxford, Richard Doll Building, Roosevelt Drive, Oxford OX3 7LF, UKDepartment of Metabolic and Vascular HealthWarwick Medical School, University of Warwick, Coventry, UKDepartment of Children and Young People and FamiliesNational Institute for Health and Welfare, Oulu, FinlandDepartment of Obstetrics and GynaecologyOulu University Hospital and University of Oulu, Oulu, FinlandOxford Centre for DiabetesEndocrinology and Metabolism, University of Oxford, Oxford, UKWellcome Trust Centre for Human GeneticsUniversity of Oxford, Oxford, UKDepartment of Surgery and CancerImperial College London, Institute of
| | - J S Tapanainen
- Cancer Epidemiology UnitNuffield Department of Population Health, University of Oxford, Richard Doll Building, Roosevelt Drive, Oxford OX3 7LF, UKDepartment of Metabolic and Vascular HealthWarwick Medical School, University of Warwick, Coventry, UKDepartment of Children and Young People and FamiliesNational Institute for Health and Welfare, Oulu, FinlandDepartment of Obstetrics and GynaecologyOulu University Hospital and University of Oulu, Oulu, FinlandOxford Centre for DiabetesEndocrinology and Metabolism, University of Oxford, Oxford, UKWellcome Trust Centre for Human GeneticsUniversity of Oxford, Oxford, UKDepartment of Surgery and CancerImperial College London, Institute of Reproductive and Developmental Biology, London, UKDepartment of Epidemiology and BiostatisticsImperial College London, MRC-Health Protection Agency Centre for Environment and Health, and School of Public Health, London, UKInstitute of Health SciencesUniversity of Oulu, Oulu, FinlandBiocenter OuluUniversity of Oulu, Oulu, FinlandUnit of Primary CareOulu University Hospital, Oulu, FinlandDepartment of Obstetrics and GynecologyHelsinki University Central Hospital and University of Helsinki, Helsinki, FinlandDepartment of Clinical ChemistryUniversity of Oulu, Oulu, FinlandNorLab OuluOulu University Hospital, Oulu, FinlandCancer Epidemiology UnitNuffield Department of Population Health, University of Oxford, Richard Doll Building, Roosevelt Drive, Oxford OX3 7LF, UKDepartment of Metabolic and Vascular HealthWarwick Medical School, University of Warwick, Coventry, UKDepartment of Children and Young People and FamiliesNational Institute for Health and Welfare, Oulu, FinlandDepartment of Obstetrics and GynaecologyOulu University Hospital and University of Oulu, Oulu, FinlandOxford Centre for DiabetesEndocrinology and Metabolism, University of Oxford, Oxford, UKWellcome Trust Centre for Human GeneticsUniversity of Oxford, Oxford, UKDepartment of Surgery and CancerImperial College London, Institute of
| | - A Ruokonen
- Cancer Epidemiology UnitNuffield Department of Population Health, University of Oxford, Richard Doll Building, Roosevelt Drive, Oxford OX3 7LF, UKDepartment of Metabolic and Vascular HealthWarwick Medical School, University of Warwick, Coventry, UKDepartment of Children and Young People and FamiliesNational Institute for Health and Welfare, Oulu, FinlandDepartment of Obstetrics and GynaecologyOulu University Hospital and University of Oulu, Oulu, FinlandOxford Centre for DiabetesEndocrinology and Metabolism, University of Oxford, Oxford, UKWellcome Trust Centre for Human GeneticsUniversity of Oxford, Oxford, UKDepartment of Surgery and CancerImperial College London, Institute of Reproductive and Developmental Biology, London, UKDepartment of Epidemiology and BiostatisticsImperial College London, MRC-Health Protection Agency Centre for Environment and Health, and School of Public Health, London, UKInstitute of Health SciencesUniversity of Oulu, Oulu, FinlandBiocenter OuluUniversity of Oulu, Oulu, FinlandUnit of Primary CareOulu University Hospital, Oulu, FinlandDepartment of Obstetrics and GynecologyHelsinki University Central Hospital and University of Helsinki, Helsinki, FinlandDepartment of Clinical ChemistryUniversity of Oulu, Oulu, FinlandNorLab OuluOulu University Hospital, Oulu, FinlandCancer Epidemiology UnitNuffield Department of Population Health, University of Oxford, Richard Doll Building, Roosevelt Drive, Oxford OX3 7LF, UKDepartment of Metabolic and Vascular HealthWarwick Medical School, University of Warwick, Coventry, UKDepartment of Children and Young People and FamiliesNational Institute for Health and Welfare, Oulu, FinlandDepartment of Obstetrics and GynaecologyOulu University Hospital and University of Oulu, Oulu, FinlandOxford Centre for DiabetesEndocrinology and Metabolism, University of Oxford, Oxford, UKWellcome Trust Centre for Human GeneticsUniversity of Oxford, Oxford, UKDepartment of Surgery and CancerImperial College London, Institute of
| | - I T Huhtaniemi
- Cancer Epidemiology UnitNuffield Department of Population Health, University of Oxford, Richard Doll Building, Roosevelt Drive, Oxford OX3 7LF, UKDepartment of Metabolic and Vascular HealthWarwick Medical School, University of Warwick, Coventry, UKDepartment of Children and Young People and FamiliesNational Institute for Health and Welfare, Oulu, FinlandDepartment of Obstetrics and GynaecologyOulu University Hospital and University of Oulu, Oulu, FinlandOxford Centre for DiabetesEndocrinology and Metabolism, University of Oxford, Oxford, UKWellcome Trust Centre for Human GeneticsUniversity of Oxford, Oxford, UKDepartment of Surgery and CancerImperial College London, Institute of Reproductive and Developmental Biology, London, UKDepartment of Epidemiology and BiostatisticsImperial College London, MRC-Health Protection Agency Centre for Environment and Health, and School of Public Health, London, UKInstitute of Health SciencesUniversity of Oulu, Oulu, FinlandBiocenter OuluUniversity of Oulu, Oulu, FinlandUnit of Primary CareOulu University Hospital, Oulu, FinlandDepartment of Obstetrics and GynecologyHelsinki University Central Hospital and University of Helsinki, Helsinki, FinlandDepartment of Clinical ChemistryUniversity of Oulu, Oulu, FinlandNorLab OuluOulu University Hospital, Oulu, Finland
| | - H Martikainen
- Cancer Epidemiology UnitNuffield Department of Population Health, University of Oxford, Richard Doll Building, Roosevelt Drive, Oxford OX3 7LF, UKDepartment of Metabolic and Vascular HealthWarwick Medical School, University of Warwick, Coventry, UKDepartment of Children and Young People and FamiliesNational Institute for Health and Welfare, Oulu, FinlandDepartment of Obstetrics and GynaecologyOulu University Hospital and University of Oulu, Oulu, FinlandOxford Centre for DiabetesEndocrinology and Metabolism, University of Oxford, Oxford, UKWellcome Trust Centre for Human GeneticsUniversity of Oxford, Oxford, UKDepartment of Surgery and CancerImperial College London, Institute of Reproductive and Developmental Biology, London, UKDepartment of Epidemiology and BiostatisticsImperial College London, MRC-Health Protection Agency Centre for Environment and Health, and School of Public Health, London, UKInstitute of Health SciencesUniversity of Oulu, Oulu, FinlandBiocenter OuluUniversity of Oulu, Oulu, FinlandUnit of Primary CareOulu University Hospital, Oulu, FinlandDepartment of Obstetrics and GynecologyHelsinki University Central Hospital and University of Helsinki, Helsinki, FinlandDepartment of Clinical ChemistryUniversity of Oulu, Oulu, FinlandNorLab OuluOulu University Hospital, Oulu, Finland
| |
Collapse
|
8
|
Ijäs H, Morin-Papunen L, Keränen AK, Bloigu R, Ruokonen A, Puukka K, Ebeling T, Raudaskoski T, Vääräsmäki M. Pre-pregnancy overweight overtakes gestational diabetes as a risk factor for subsequent metabolic syndrome. Eur J Endocrinol 2013; 169:605-11. [PMID: 23959786 DOI: 10.1530/eje-13-0412] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
OBJECTIVE Gestational diabetes mellitus (GDM) is associated with an increased risk of subsequent diabetes and metabolic syndrome (MS). The independent significance of overweight, often associated with GDM, is controversial. This study was aimed to investigate the prevalence of MS and carotid intima-media thickness (CIMT) values in normal and overweight women with previous insulin-treated GDM and control without GDM 19 years after the index pregnancy. METHODS The study group consisted of 61 women with prior GDM and 55 controls who gave birth in Oulu University Hospital between 1988 and 1993. These women were further divided into subgroups according to pre-pregnancy BMI (<25 or ≥25 kg/m(2)). In 2008-2010, anthropometrics and blood pressure were measured, blood samples were taken, and an oral glucose tolerance test was performed to investigate the components of MS. CIMT was measured by Doppler ultrasound. RESULTS Total prevalence of MS was 62% in the GDM group and 31% in the control group (P=0.001); it was highest (86%) in GDM women with pre-pregnancy overweight. CIMT was significantly thicker (0.67 vs 0.56 mm, P=0.007) and more often abnormal (71.7 vs 45.3%, P=0.004) in the GDM group compared with the controls. In logistic regression analysis, the strongest factor predicting MS in the whole study population was pre-pregnancy overweight. CONCLUSIONS Pre-pregnancy overweight was the strongest predictive factor for later MS, whereas GDM indicated increased risk of subsequent diabetes and subclinical atherosclerosis. The risk of MS was highest when both of these factors were present.
Collapse
Affiliation(s)
- H Ijäs
- Departments of Obstetrics and Gynecology Radiology, Oulu University Hospital, PO Box 23, FIN-90029 OYS Oulu, Finland
| | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Sovio U, Kaakinen M, Tzoulaki I, Das S, Ruokonen A, Pouta A, Hartikainen AL, Molitor J, Järvelin MR. How do changes in body mass index in infancy and childhood associate with cardiometabolic profile in adulthood? Findings from the Northern Finland Birth Cohort 1966 Study. Int J Obes (Lond) 2013; 38:53-9. [PMID: 24080793 DOI: 10.1038/ijo.2013.165] [Citation(s) in RCA: 61] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/06/2013] [Revised: 08/09/2013] [Accepted: 08/27/2013] [Indexed: 01/03/2023]
Abstract
BACKGROUND/OBJECTIVE Postnatal growth patterns leading to obesity may have adverse influences on future cardiometabolic health. This study evaluated age and body mass index (BMI) at infant BMI peak (BMIP) and childhood BMI rebound (BMIR) in relation to adult cardiometabolic outcomes in the Northern Finland Birth Cohort 1966. METHODS BMI at various ages was calculated from frequent height and weight measurements obtained from child health and welfare clinical records. Age and BMI at BMIP and BMIR were derived from random effect models fitted at >0-1.5 years (N=3 265) and >1.5-13 years (N=4 121). Cardiometabolic outcomes were obtained from a clinical examination at age 31 years. Multiple regression models were used to analyse associations between the derived growth parameters and cardiometabolic outcomes. RESULTS Age and BMI at BMIP were positively associated with adult BMI and waist circumference (WC), independently of birth weight and infant height growth (P<0.05). Later BMIR was associated with a better cardiometabolic profile: adult BMI and insulin were 14% lower, WC and triglycerides were 10% lower and the odds of metabolic syndrome (MetS) were 74% lower per 2 s.d. (1.86 years) higher age at BMIR (P<0.0001). BMI at rebound had generally weaker associations with cardiometabolic outcomes, which attenuated after adjustment for age at BMIR. CONCLUSIONS Age and BMI at infant BMIP were associated with adult adiposity but not with other cardiometabolic outcomes. Earlier timing of BMIR was a risk factor of an adverse cardiometabolic profile, independently of early growth or BMI at rebound. Identifying growth patterns harmful to cardiovascular health will give opportunities for early interventions.
Collapse
Affiliation(s)
- U Sovio
- 1] Department of Non-communicable Disease Epidemiology, Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, UK [2] Department of Epidemiology and Biostatistics, MRC-HPA Centre, School of Public Health, Imperial College London, Norfolk Place, London, UK
| | - M Kaakinen
- 1] Institute of Health Sciences, University of Oulu, Oulu, Finland [2] Biocenter Oulu, University of Oulu, Oulu, Finland
| | - I Tzoulaki
- 1] Department of Epidemiology and Biostatistics, MRC-HPA Centre, School of Public Health, Imperial College London, Norfolk Place, London, UK [2] Department of Hygiene and Epidemiology, Medical School University of Ioannina, Ioannina, Greece
| | - S Das
- Department of Epidemiology and Biostatistics, MRC-HPA Centre, School of Public Health, Imperial College London, Norfolk Place, London, UK
| | - A Ruokonen
- Institute of Diagnostics, Clinical Chemistry, University of Oulu, Oulu, Finland
| | - A Pouta
- 1] Department of Children, Young People and Families, National Institute for Health and Welfare, Oulu, Finland [2] Department of Clinical Sciences/Obstetrics and Gynecology, University of Oulu, Oulu, Finland
| | - A-L Hartikainen
- Department of Clinical Sciences/Obstetrics and Gynecology, University of Oulu, Oulu, Finland
| | - J Molitor
- 1] Department of Epidemiology and Biostatistics, MRC-HPA Centre, School of Public Health, Imperial College London, Norfolk Place, London, UK [2] College of Public Health & Human Sciences, Oregon State University, Corvallis, OR, USA
| | - M-R Järvelin
- 1] Department of Epidemiology and Biostatistics, MRC-HPA Centre, School of Public Health, Imperial College London, Norfolk Place, London, UK [2] Institute of Health Sciences, University of Oulu, Oulu, Finland [3] Biocenter Oulu, University of Oulu, Oulu, Finland [4] Department of Children, Young People and Families, National Institute for Health and Welfare, Oulu, Finland
| |
Collapse
|
10
|
Kallio S, Puurunen J, Ruokonen A, Piltonen T, Tapanainen J. Anti-müllerian hormone as a marker of follicular inhibition by combined contraception – a randomized study. Fertil Steril 2012. [DOI: 10.1016/j.fertnstert.2012.07.020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
11
|
Pinola P, Lashen H, Bloigu A, Puukka K, Ulmanen M, Ruokonen A, Martikainen H, Pouta A, Franks S, Hartikainen AL, Järvelin MR, Morin-Papunen L. Menstrual disorders in adolescence: a marker for hyperandrogenaemia and increased metabolic risks in later life? Finnish general population-based birth cohort study. Hum Reprod 2012; 27:3279-86. [PMID: 22933528 DOI: 10.1093/humrep/des309] [Citation(s) in RCA: 37] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
Abstract
STUDY QUESTION Are self-reported menstrual disorders associated with hyperandrogenaemia and metabolic disturbances as early as in adolescence? SUMMARY ANSWER Menstrual disorders at the age 16 are a good marker of hyperandrogenaemia, and an adverse lipid profile was associated with higher androgen levels. WHAT IS KNOWN AND WHAT THIS PAPER ADDS Hyperandrogenism per se has been suggested to be a significant metabolic risk factor in women and a cause of physical and psychological morbidity in adolescent girls. A weak positive correlation has been described between hyperandrogenaemia and obesity in adolescent girls, but the clinical consequences are still poorly understood. Hyperandrogenism and insulin resistance are also key features of polycystic ovary syndrome (PCOS), and women with PCOS are consequently at an increased risk of developing type 2 diabetes mellitus and/or metabolic syndrome, and may have increased cardiovascular morbidity. Our findings confirm that the association between menstrual disorders, hyperandrogenism, obesity and metabolic risks is already evident in adolescence. STUDY DESIGN This population-based, cross-sectional study used postal questionnaires to targeting 15-16-year-old girls in the Northern Finland Birth Cohort 1986 (n= 4567). PARTICIPANTS AND SETTING There were 3669 girls who answered the postal questionnaire and out of 3373 girls who also underwent clinical examinations and blood tests, 2448 were included in the analyses. The questionnaire included one question about the regularity and length of the menstrual cycle: 'Is your menstrual cycle (the interval from the beginning of one menstrual period to the beginning of the next period) often (more than twice a year) longer than 35 days?' The girls who answered 'yes' to this question were considered to be suffering from menstrual disorders and were classified as 'symptomatic'. The girls who answered 'no' were defined as 'non-symptomatic'. MAIN RESULTS AND THE ROLE OF CHANCE There were 709 (29%) girls who reported menstrual disorders (symptomatic girls) and 1739 who had regular periods (non-symptomatic girls). In the whole population and in both study groups, there were significant correlations between body mass index (BMI) (and waist-to-hip ratio), hyperandrogenaemia and metabolic parameters. Symptomatic girls exhibited significantly higher serum concentrations of testosterone (P= 0.010), lower levels of sex hormone-binding globulin (P =0.042) and higher free androgen indices [FAIs; geometric mean 3.38 (interquartile range (IQR): 2.27, 5.18) versus 3.08 (IQR: 2.15, 4.74), P= 0.002]. The two groups had comparable BMI and insulin sensitivity, and serum levels of glucose, insulin and lipids. There was a significant linear trend towards higher FAI values in the higher BMI quartiles in both symptomatic and non-symptomatic girls. In the whole population, there was a statistically significant linear decrease in high-density lipoprotein concentrations (P < 0.001) and higher triglyceride concentrations (P =0.004) in the upper FAI quartile. IMPLICATIONS Information regarding menstrual disorders in adolescence is a good marker of hyperandrogenaemia and may be an early risk factor for the development of PCOS in adulthood. The association between obesity, hyperandrogenism and metabolic risks is already evident in adolescence, which strengthens the importance of noting menstrual disorders at an early stage. BIAS, LIMITATIONS, GENERALIZABILITY: The cross-sectional nature of the study does not allow us to draw conclusions concerning the metabolic risks of this population in later life. The diagnosis of menstrual disorders was based on a questionnaire, suggesting a risk of information bias in reporting the symptoms. This study was not designed to diagnose PCOS, as ultrasonography was not available and there was no clinical evaluation of hyperandrogenism (i.e. hirsutism). However, we were able to take into account potential confounding factors in the analyses. STUDY FUNDING/COMPETING INTERESTS This work was supported by grants from the Finnish Medical Society Duodecim, the North Ostrobothnia Regional Fund, the Academy of Finland (project grants 104781, 120315, 129269, 1114194, SALVE), University Hospital Oulu, Biocenter, University of Oulu, Finland (75617), the European Commission (EURO-BLCS, Framework 5 award QLG1-CT-2000-01643) and the Medical Research Council, UK (PrevMetSyn/SALVE). None of the authors have any conflict of interest to declare.
Collapse
Affiliation(s)
- P Pinola
- Department of Obstetrics and Gynaecology, University Hospital of Oulu, PL 23 90029 OYS, Oulu, Finland
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Piltonen T, Puurunen J, Hedberg P, Ruokonen A, Mutt SJ, Herzig KH, Nissinen A, Morin-Papunen L, Tapanainen JS. Oral, transdermal and vaginal combined contraceptives induce an increase in markers of chronic inflammation and impair insulin sensitivity in young healthy normal-weight women: a randomized study. Hum Reprod 2012; 27:3046-56. [PMID: 22811306 DOI: 10.1093/humrep/des225] [Citation(s) in RCA: 53] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022] Open
Abstract
STUDY QUESTION What is the effect of alternative administration routes of combined contraceptives (CCs) on androgen secretion, chronic inflammation, glucose tolerance and lipid profile? SUMMARY ANSWER The use of oral, transdermal and vaginal CCs impairs glucose tolerance and induces chronic inflammation. WHAT IS KNOWN AND WHAT THIS PAPER ADDS Oral CCs worsen insulin sensitivity and are associated with increased levels of circulating inflammatory markers, whereas the metabolic effects of transdermal and vaginal CCs have been reported to be minimal. This is the first study comparing three different administration routes of CCs on metabolic variables. STUDY DESIGN, SIZE AND DURATION This randomized (computer-generated) open-label 9-week follow-up study was conducted at the Oulu University Hospital, Finland. Fasting blood samples were collected at baseline and thereafter at 5 and 9 weeks of treatment, and serum levels of 17-hydroxyprogesterone, androstenedione, testosterone, C-reactive protein (CRP), sex hormone-binding globulin (SHBG), glucose, insulin, C-peptide, total, low-density lipoprotein and high-density lipoprotein cholesterol and triglycerides were measured. Oral glucose tolerance tests were performed and plasma levels of pentraxin 3 (PTX-3) were measured at 0 and 9 weeks. The randomization list, with an allocation ratio of 1:1:1 and block size of six, was computer generated and constructed by a pharmacist at the Oulu University Hospital. The research nurse controlled the randomization list and assigned participants to their groups at the first visit. PARTICIPANTS AND SETTING Forty-two of 54 healthy women who entered the study used oral contraceptive pills (n = 13), transdermal contraceptive patches (n = 15) or contraceptive vaginal rings (n = 14) continuously for 9 weeks. Inclusion criteria were regular menstrual cycles, at least a 2-month washout as regards hormonal contraceptives and no medication. MAIN RESULTS AND THE ROLE OF CHANCE Serum levels of SHBG increased and consequently the free androgen index (FAI) decreased in all study groups from baseline to 9 weeks of treatment [FAI, oral: 1.3 (95% confidence interval, CI: 0.94; 1.62) to 0.40 (0.25; 0.54); transdermal: 1.2 (0.96; 1.4) to 0.36 (0.30; 0.43); vaginal: 1.6 (1.1; 2.1) to 0.43 (0.29; 0.58), P < 0.001 in all groups]. Insulin sensitivity was reduced at 9 weeks in all three groups according to the Matsuda index [oral: 7.3 (5.5; 9.0) to 5.6 (3.9; 7.3); transdermal: 9.1 (6.7; 11.4) to 6.6 (4.5; 8.8); vaginal: 7.7 (5.9; 9.5) to 5.4 (3.9; 7.0), P= 0.004-0.024]. Levels of HDL cholesterol, triglycerides and CRP rose in all three groups [CRP, oral: 0.70 (0.38; 1.0) to 5.4 (1.0; 9.9) mg/l; transdermal: 0.77 (0.45; 1.1) to 2.9 (1.4;4.4) mg/l; vaginal: 0.98 (0.52; 1.4) to 3.7 (-0.25; 7.7, a negative value due to skewed distribution to right) mg/l, P≤ 0.002 in all groups] and PTX-3 levels increased in the oral and transdermal study groups (P = 0.007 and P = 0.002). WIDER IMPLICATIONS OF THE FINDINGS Although the long-term consequences of the present results remain undetermined, these findings emphasize the importance of monitoring glucose metabolism during the use of CCs, especially in women with known risks of type 2 diabetes or cardiovascular diseases. BIAS, LIMITATIONS, GENERALIZABILITY: The number of subjects was relatively low. Moreover, the 9-week exposure to CCs is too short to draw conclusions about the long-term health consequences. However, as the subjects were healthy, normal-weight young women, the possible alterations in the glucose and inflammatory profiles among women with known metabolic risks might be even greater. STUDY FUNDING/COMPETING INTERESTS This work was supported by grants from the Academy of Finland, the Sigrid Jusélius Foundation, the Finnish Medical Foundation, the Research Foundation of Obstetrics and Gynecology, Oulu University Scholarship Foundation, the North Ostrobothnia Regional Fund of the Finnish Cultural Foundation, the Tyyni Tani Foundation of the University of Oulu and the Finnish-Norwegian Medical Foundation. No competing interests. TRIAL REGISTRATION NUMBER NCT01087879.
Collapse
Affiliation(s)
- T Piltonen
- Department of Obstetrics and Gynecology, Oulu University Hospital, Oulu FIN-90029, Finland
| | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Barad D, Gupta A, Gleicher N, Puurunen J, Piltonen T, Morin-Papunen L, Ruokonen A, Tapanainen JS, Villarroel C, Lopez P, Merino P, Van Velzen A, Iniguez G, Codner E, El-Sherbiny W, Al-Inany H, Ibrahim M, Harb H, Richardson M, Yew HC, Simonis CD, Byrne CD, Cheong Y, Matteo M, Greco P, Santopietro X, Noviello A, De Rosario M, Cho Y, Falagario T, Totaro R, Massenzio F, Liso A, Serviddio G, Garcia-Gamon M, Romeu M, Monzo A, Montanana V, Perez-Calvo A, Tresguerres J, Romeu A. Session 55: PCOS 2. Hum Reprod 2010. [DOI: 10.1093/humrep/de.25.s1.55] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
14
|
Tso LO, Costello MF, Andriolo RB, Albuquerque LE, Freitas V, Morin - Papunen L, Rantala A, Unkila-Kallio L, Tiitinen A, Hippelainen M, Tinkanen H, Perheentupa A, Ruokonen A, Tapanainen JS, Tang T, Barth JH, Balen AH, Lee K, Choi YS, Yang H, Seo SK, Kim HY, Lee BS, Germeyer A, Jauckus J, Zorn M, Toth B, Capp E, Strowitzki T. Session 45: PCOS1. Hum Reprod 2010. [DOI: 10.1093/humrep/de.25.s1.45] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
15
|
Niinimäki M, Ruokonen A, Tapanainen JS, Järvelä IY. Effect of mifepristone on the corpus luteum in early pregnancy. Ultrasound Obstet Gynecol 2009; 34:448-53. [PMID: 19610012 DOI: 10.1002/uog.6418] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/25/2023]
Abstract
OBJECTIVE The antiprogestin mifepristone is widely used for medical termination of pregnancy (TOP). Previous studies have suggested that the mechanism of mifepristone is based on its action in the endometrium and myometrium. The aim of this study was to evaluate the possible effects of mifepristone on corpus luteum activity. METHODS This was a prospective, longitudinal controlled study to which 20 patients undergoing medical TOP (study group) and 20 patients with normal ongoing pregnancy (control group) were recruited. Medical TOP was induced with 200 mg of mifepristone followed by 0.8 mg of misoprostol 2 days later. Three-dimensional ultrasound examinations and hormone assays (progesterone, human chorionic gonadotropin, and 17-hydroxyprogesterone) were performed in both groups on the day of, and 2 days after, administration of mifepristone. Total volume (vascularized + non-vascularized) of the dominant (containing corpus luteum) and non-dominant ovary and serum hormone levels were measured. RESULTS After administration of mifepristone, a decrease in serum progesterone levels was observed with a simultaneous decrease in the non-vascularized volume of the dominant ovary in the study group. No such changes were observed in the control group. CONCLUSIONS The observations indicate that, in addition to trophoblastic tissue, the corpus luteum is also the target of mifepristone.
Collapse
Affiliation(s)
- M Niinimäki
- Department of Obstetrics and Gynecology, Oulu University Hospital, Oulu, Finland.
| | | | | | | |
Collapse
|
16
|
Vierimaa O, Villablanca A, Alimov A, Georgitsi M, Raitila A, Vahteristo P, Larsson C, Ruokonen A, Eloranta E, Ebeling TML, Ignatius J, Aaltonen LA, Leisti J, Salmela PI. Mutation analysis of MEN1, HRPT2, CASR, CDKN1B, and AIP genes in primary hyperparathyroidism patients with features of genetic predisposition. J Endocrinol Invest 2009; 32:512-8. [PMID: 19474519 DOI: 10.1007/bf03346498] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Abstract
OBJECTIVE Primary hyperparathyroidism (PHPT), a common endocrine condition, is usually caused by sporadically occurring parathyroid adenoma. A subset of patients carry germline mutations in genes such as MEN1 (multiple endocrine neoplasia type 1), HRPT2 (hyperparathyroidism 2), and CASR (calcium-sensing receptor) predisposing to syndromic forms of PHPT or familial isolated hyperparathyroidism (FIHP). Recently, germline mutations in two novel genes AIP (aryl hydrocarbon receptor-interacting protein) and CDKN1B (cyclin-dependent kinase inhibitor 1B) have been found to be associated with endocrine tumors. The purpose of this study was to evaluate the role of MEN1, HRPT2, CASR, AIP, and CDKN1B genes in PHPT patients with clinical features suggestive of genetic predisposition. PATIENTS AND DESIGN Medical records of patients treated for PHPT from 1974 to 2001 at Oulu University Hospital were reviewed. Patients with multiglandular or recurrent/persistent disease, other MEN1- related manifestations, aged 40 yr or younger at onset or with a family history of PHPT/MEN1-related tumor were invited to the study. Twenty patients with previously diagnosed MEN1 were excluded. Participants were interviewed and blood samples obtained for biochemical screening and mutation analysis of MEN1, HRPT2, CASR, AIP, and CDKN1B. RESULTS Of the 56 invited patients, 29 took part in the study. One patient was found to carry the c. 1356_1367del12 MEN1 founder mutation. Mutations in other genes were not detected. CONCLUSIONS Apart from MEN1, mutations in other genes predisposing to PHPT seem to be rare or non-existing in Northern Finnish PHPT patients. No evidence was found for a role of AIP or CDKN1B in PHPT predisposition.
Collapse
Affiliation(s)
- O Vierimaa
- Department of Clinical Genetics, Oulu University Hospital, PB 24, FIN-90029 Oys, Oulu, Finland.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Pirkola J, Tammelin T, Bloigu A, Pouta A, Laitinen J, Ruokonen A, Tapanainen P, Järvelin MR, Vääräsmäki M. Prevalence of metabolic syndrome at age 16 using the International Diabetes Federation paediatric definition. Arch Dis Child 2008; 93:945-51. [PMID: 18456683 DOI: 10.1136/adc.2007.132951] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
OBJECTIVE We estimated the prevalence of metabolic syndrome (MS) in adolescents, using the new International Diabetes Federation (IDF) paediatric definition and compared this with prevalence estimated using the IDF adult definition and five other previously published definitions. DESIGN Cross-sectional survey in the prospective general population-based Northern Finland Birth Cohort 1986 (NFBC 1986) at age 16 years. SETTING Birth cohort in Finland. PARTICIPANTS 5665 adolescents (2862 males and 2803 females) clinically examined in 2001-2002. MAIN OUTCOME MEASURES The prevalence of MS using different definitions. RESULTS The overall prevalence of MS using the IDF paediatric definition was 2.4% (95% CI 2.0 to 2.8%) at the age of 16 years. Using the IDF adult definition the overall prevalence was lower, 1.7% (CI 1.3 to 2.0%, European cut-offs for waist circumference) and 1.0% (CI 0.7 to 1.3%, North American cut-offs). CONCLUSION In 16-year-old adolescents, the paediatric IDF definition rendered a higher prevalence estimate than the adult definition.
Collapse
Affiliation(s)
- J Pirkola
- Department of Obstetrics and Gynecology, Oulu University Hospital, Oulu, Finland.
| | | | | | | | | | | | | | | | | |
Collapse
|
18
|
Koponen H, Vuononvirta J, Mäki P, Miettunen J, Moilanen I, Taanila A, Ruokonen A, Veijola J. No difference in insulin resistance and lipid levels between controls and adolescent subjects who later develop psychosis. Schizophr Res 2008; 104:31-5. [PMID: 18590951 DOI: 10.1016/j.schres.2008.05.021] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/25/2008] [Revised: 05/17/2008] [Accepted: 05/25/2008] [Indexed: 11/24/2022]
Abstract
Type 2 diabetes and dyslipidemias co-occur frequently with psychoses, but it is not known how common they are in adolescents who later develop psychosis. We investigated waist circumference, blood glucose, lipid and insulin levels and insulin resistance in the Northern Finland 1986 Birth Cohort at the age of 15/16 (N=5410). The Social Insurance Institute register and the Finnish Hospital Discharge Register were used to find the participants who developed psychosis (N=21), and they were compared with other participants. There were no differences in the cardiometabolic variables, suggesting that psychotic episode is not preceded by glucose and lipid metabolism disturbances.
Collapse
Affiliation(s)
- H Koponen
- Department of Psychiatry, University of Kuopio and University Hospital of Kuopio, P.O. Box 1777, FIN-70211 Kuopio, Finland.
| | | | | | | | | | | | | | | |
Collapse
|
19
|
|
20
|
Barber TM, Bennett AJ, Groves CJ, Sovio U, Ruokonen A, Martikainen H, Pouta A, Hartikainen AL, Elliott P, Lindgren CM, Freathy RM, Koch K, Ouwehand WH, Karpe F, Conway GS, Wass JAH, Järvelin MR, Franks S, McCarthy MI. Association of variants in the fat mass and obesity associated (FTO) gene with polycystic ovary syndrome. Diabetologia 2008; 51:1153-8. [PMID: 18478198 DOI: 10.1007/s00125-008-1028-6] [Citation(s) in RCA: 90] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/26/2008] [Accepted: 04/08/2008] [Indexed: 11/29/2022]
Abstract
AIMS/HYPOTHESIS Variants in the fat-mass and obesity-associated gene (FTO) influence susceptibility to type 2 diabetes via an effect on adiposity/obesity. Given the important role of obesity in the aetiology of both polycystic ovary syndrome (PCOS) and type 2 diabetes mellitus, our aim was to establish whether FTO variants are also implicated in PCOS susceptibility. METHODS We performed a genetic association study of FTO variant rs9939609 using case-control analyses, conducted in 463 PCOS patients (geometric mean BMI 27.5 kg/m(2)) and 1,336 female controls (geometric mean BMI 25.3 kg/m(2)) of UK British/Irish origin. We also sought evidence for associations between FTO variation and circulating testosterone levels in 324 UK PCOS patients and 1,000 women from the Northern Finland Birth Cohort of 1966. Outcome measures included FTO rs9939609 genotype frequencies by participant group and androgen measures (testosterone, free androgen index) by genotype. RESULTS There was a significant association between FTO genotype and PCOS status in the UK case-control analysis, which was attenuated by adjustment for BMI (Cochran-Armitage test, odds ratio [per minor allele copy] 1.30 [95% CI 1.12, 1.51], p = 7.2 x 10(-4) [unadjusted], p = 2.9 x 10(-3) [adjusted]). This association was most evident in obese PCOS patients (PCOS patients below median BMI vs UK controls, p = 0.11; above median BMI vs controls, p = 2.9 x 10(-4)). No relationship between FTO genotype and androgen levels was seen. CONCLUSIONS/INTERPRETATION We provide the first evidence that variants that predispose to common obesity also result in altered susceptibility to PCOS, confirming the mechanistic link between these conditions. The predominant effect of FTO variants on PCOS susceptibility is probably mediated through adiposity.
Collapse
Affiliation(s)
- T M Barber
- Oxford Centre for Diabetes, Endocrinology and Metabolism, Churchill Hospital, Oxford, OX3 7LJ, UK.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Koivunen R, Pouta A, Franks S, Martikainen H, Sovio U, Hartikainen AL, McCarthy M, Ruokonen A, Bloigu A, Jarvelin MR, Morin-Papunen L. Fecundability and spontaneous abortions in women with self-reported oligo-amenorrhea and/or hirsutism: Northern Finland Birth Cohort 1966 Study. Hum Reprod 2008; 23:2134-9. [DOI: 10.1093/humrep/den136] [Citation(s) in RCA: 61] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
22
|
Koponen H, Mäki P, Halonen H, Miettunen J, Laitinen J, Tammelin T, Moilanen I, Taanila A, Ruokonen A, Korkeila J, Veijola J. Insulin resistance and lipid levels in adolescents with familial risk for psychosis. Acta Psychiatr Scand 2008; 117:337-41. [PMID: 18241302 DOI: 10.1111/j.1600-0447.2008.01154.x] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
OBJECTIVE Type 2 diabetes and dyslipidemias co-occur frequently with schizophrenia. It is not known how common they are in adolescents with a familial risk for psychosis. METHOD The Northern Finland 1986 Birth Cohort consists of 9432 children born alive in the two Northernmost provinces in Finland. At the age of 15/16 they participated in clinical examination including measurements of glucose, lipids and IR, and a questionnaire including items about their diet and physical activity. The Finnish Hospital Discharge Register was used to find out non-organic psychoses in parents during 1972-2000. This familial risk was found out in 54 boys and 68 girls. Their results were compared with other cohort members. RESULTS No differences were observed in the cardiometabolic risk factors between the study groups. CONCLUSION Our results suggest that familial risk for psychosis is not directly associated with disturbances of glucose and lipid metabolism among adolescents.
Collapse
Affiliation(s)
- H Koponen
- Department of Psychiatry, University of Kuopio, and Academy of Finland, Kuopio, Finland.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Koivikko ML, Karsikas M, Salmela PI, Tapanainen JS, Ruokonen A, Seppänen T, Huikuri HV, Perkiömäki JS. Effects of controlled hypoglycaemia on cardiac repolarisation in patients with type 1 diabetes. Diabetologia 2008; 51:426-35. [PMID: 18097646 DOI: 10.1007/s00125-007-0902-y] [Citation(s) in RCA: 55] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/26/2007] [Accepted: 10/31/2007] [Indexed: 10/22/2022]
Abstract
AIMS/HYPOTHESIS Nocturnal hypoglycaemia may contribute to sudden death in diabetic patients. However, it is not well known why hypoglycaemia makes these patients prone to death. METHODS We assessed the effects of controlled hypoglycaemia on cardiac repolarisation using novel electrocardiographic descriptors of T-wave and QRS complex morphology in 16 type 1 diabetic patients and eight healthy counterparts. Several electrocardiographic variables characterising repolarisation were analysed from digitised 12-lead electrocardiograms during a euglycaemic and a hypoglycaemic clamp. RESULTS Hypoglycaemia did not result in significant changes either in the QT interval corrected for heart rate by the nomogram method or in QT dispersion. However, the morphology of the T-wave changed significantly during hypoglycaemia. The T-wave amplitude and area in precordial leads decreased significantly in both groups (p<0.05 to p<0.001). The spatial QRS-T angle (total cosine R to T) (p<0.05) and the height and the width of the T-wave loop (p<0.05 and p<0.01, respectively) were also reduced in the diabetic patients. The changes in the repolarisation parameters did not exhibit any significant association with changes in catecholamine levels or in heart rate variability in either group. CONCLUSIONS/INTERPRETATION Hypoglycaemia results in distinct alterations in cardiac repolarisation, which may increase the vulnerability to arrhythmic events.
Collapse
Affiliation(s)
- M L Koivikko
- Department of Internal Medicine, University of Oulu, P.O. Box 5000, (Kajaanintie 50), 90014 Oulu, Finland
| | | | | | | | | | | | | | | |
Collapse
|
24
|
Bennett AJ, Sovio U, Ruokonen A, Martikainen H, Pouta A, Hartikainen AL, Franks S, Elliott P, Järvelin MR, McCarthy MI. No evidence that established type 2 diabetes susceptibility variants in the PPARG and KCNJ11 genes have pleiotropic effects on early growth. Diabetologia 2008; 51:82-5. [PMID: 17994213 DOI: 10.1007/s00125-007-0863-1] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/25/2007] [Accepted: 09/28/2007] [Indexed: 10/22/2022]
Abstract
AIMS/HYPOTHESIS The P12A variant in the PPARG gene and the E23K polymorphism in KCNJ11 are both known to influence individual predisposition to type 2 diabetes. If the effect of these variants on insulin secretion and action were to extend to an influence on early growth (which is largely mediated by insulin), it would offer an explanation for observed associations between low birthweight and subsequent diabetes. Since previous studies of the effects of these variants on early growth have been limited and conflicting, we examined these associations in a large, well-characterised birth cohort. METHODS The P12A and E23K variants were genotyped in (respectively) 5,652 and 5,632 individuals from the Northern Finland Birth Cohort of 1966 and we sought associations with early growth phenotypes. RESULTS Neither variant was associated with birthweight (P12A, p = 0.42; E23K, p = 0.44, additive models) or other measures of early growth. Although a previous report had suggested that the P12A effect on adult insulin sensitivity was restricted to small babies, we were unable to reproduce this finding (p = 0.40), nor did we confirm a previous report of an association with gestational age (p = 0.23). CONCLUSIONS/INTERPRETATION Despite a larger sample size than previous studies, we were unable to detect any effect of these variants on early growth. These findings do not support the notion that there are shared genetic determinants of low birthweight and adult diabetes.
Collapse
Affiliation(s)
- A J Bennett
- Oxford Centre for Diabetes, Endocrinology & Metabolism, University of Oxford, Oxford, OX3 7LJ, UK
| | | | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Barber TM, Bennett AJ, Groves CJ, Sovio U, Ruokonen A, Martikainen H, Pouta A, Hartikainen AL, Elliott P, Wass JAH, Järvelin MR, Zeggini E, Franks S, McCarthy MI. Disparate genetic influences on polycystic ovary syndrome (PCOS) and type 2 diabetes revealed by a lack of association between common variants within the TCF7L2 gene and PCOS. Diabetologia 2007; 50:2318-22. [PMID: 17805508 DOI: 10.1007/s00125-007-0804-z] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/27/2007] [Accepted: 07/23/2007] [Indexed: 01/28/2023]
Abstract
AIMS/HYPOTHESIS Common variants of the gene encoding transcription factor 7-like 2 (TCF7L2) have a powerful effect on individual risk of type 2 diabetes (per allele odds ratio approximately 1.35). Polycystic ovary syndrome (PCOS) and type 2 diabetes are familial conditions sharing common features. Based on this, the aim of the present study was to establish whether variation in TCF7L2 also influences the development of PCOS. METHODS We conducted a genetic association study of variants of TCF7L2 (rs7903146 and rs12255372) using both case-control and quantitative trait approaches. Case-control analyses were conducted in (1) 369 PCOS cases and 2574 controls of UK British/Irish origin, and (2) 540 women with PCOS symptoms and 1083 controls from the Northern Finland Birth Cohort of 1966. Quantitative trait analyses (androgen levels) were also performed (1249 individuals). RESULTS There was no association between rs7903146 and PCOS in the UK case-control study (Cochran-Armitage test, p = 0.51); nor with symptomatic status in the Finnish cohort (p = 0.36). In addition, there were no relationships between the TCF7L2 single nucleotide polymorphism rs7903146 and androgen levels (UK cases, p = 0.99; Finnish controls, p = 0.57; Finnish symptomatic cases, p = 0.80). Results at rs12255372 were similar, reflecting strong linkage disequilibrium with rs7903146. CONCLUSIONS/INTERPRETATION Our study was powered to detect an effect on PCOS susceptibility similar to that previously reported for these variants on type 2 diabetes. Failure to detect any evident association with PCOS provides the strongest evidence yet that the genetic architecture of these related conditions is qualitatively distinct.
Collapse
Affiliation(s)
- T M Barber
- Oxford Centre for Diabetes, Endocrinology and Metabolism, Churchill Hospital, Old Road, Headington, Oxford OX3 7LJ, UK.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
26
|
Majuri A, Santaniemi M, Rautio K, Kunnari A, Vartiainen J, Ruokonen A, Kesäniemi YA, Tapanainen JS, Ukkola O, Morin-Papunen L. Rosiglitazone treatment increases plasma levels of adiponectin and decreases levels of resistin in overweight women with PCOS: a randomized placebo-controlled study. Eur J Endocrinol 2007; 156:263-9. [PMID: 17287417 DOI: 10.1530/eje.1.02331] [Citation(s) in RCA: 68] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
OBJECTIVE Abdominal obesity, insulin resistance and compensatory hyperinsulinaemia play a central role in the pathogenesis of the polycystic ovary syndrome (PCOS). Abdominal adipose tissue is a source of adipokines, such as adiponectin and resistin, both of which may be involved in the development of insulin resistance and chronic inflammation in PCOS. Ghrelin, an important regulatory peptide of food intake, may also play a role in metabolic disturbances related to PCOS. The aim of this study was to examine the effects of 4 months of treatment with the insulin sensitizer rosiglitazone on plasma adiponectin, resistin and ghrelin levels in overweight women with PCOS. DESIGN A randomised placebo-controlled study. METHODS Thirty overweight/obese women with PCOS (body mass index>25 kg/m(2), mean age 29.1+/- 1.2 (S.E.M.) years) were randomly allocated to either rosiglitazone (Avandia, 4 mg twice a day) or placebo treatment. Plasma levels of adiponectin, resistin and ghrelin and their correlation to serum levels of insulin, C-peptide and steroid hormones, and insulin sensitivity (euglycaemic hyperinsulinaemic clamp) were assessed. RESULTS Adiponectin and ghrelin levels correlated significantly with most metabolic markers of insulin resistance and with serum levels of DHEA and 17-hydroxyprogesterone. Plasma levels of adiponectin increased from 9.26+/-0.90 (S.E.M.) to 22.22+/-3.66 microg/ml (P<0.001) and those of resistin decreased from 12.57+/-1.63 to 9.21+/-0.53 ng/ml (P=0.009) at 4 months of treatment, but plasma ghrelin levels did not change. CONCLUSIONS Rosiglitazone had beneficial effects on serum levels of adiponectin and resistin, suggesting that these adipocytokines may contribute to the improvement in insulin sensitivity observed during the treatment.
Collapse
Affiliation(s)
- A Majuri
- Department of Obstetrics and Gynaecology, University Hospital of Oulu, Finland
| | | | | | | | | | | | | | | | | | | |
Collapse
|
27
|
Rautio K, Tapanainen JS, Ruokonen A, Morin-Papunen LC. Endocrine and metabolic effects of rosiglitazone in overweight women with PCOS: a randomized placebo-controlled study. Hum Reprod 2006; 21:1400-7. [PMID: 16501039 DOI: 10.1093/humrep/dei505] [Citation(s) in RCA: 71] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023] Open
Abstract
BACKGROUND The objective of the study was to assess the therapeutic effects of rosiglitazone in overweight women with polycystic ovary syndrome (PCOS). METHODS A double-blind, placebo-controlled study was conducted on 30 (BMI > 25 kg/m2, mean age 29.1 +/- 1.2 years) overweight women with PCOS treated with rosiglitazone or placebo for 4 months. Waist-to-hip ratios (WHRs), serum concentrations of sex hormones and binding proteins, blood glucose, serum insulin and serum C-peptide during a 75-g oral glucose tolerance test (OGTT), first-phase insulin secretion as determined by an intravenous glucose tolerance test (IVGTT), M values (expressing insulin sensitivity using a euglycaemic clamp) and calorimetric data were assessed at 0 and 4 months of treatment. RESULTS Rosiglitazone improved menstrual cyclicity, increased serum sex hormone-binding globulin (SHBG) levels and decreased serum levels of androstenedione, 17-hydroxyprogesterone (17-OHP), dehydroepiandrosterone (DHEA) and dehydroepiandrosterone sulphate (DHEA-S). Glucose tolerance [expressed as AUC(glucose) during the OGTT] improved (P = 0.002) and peripheral insulin response (expressed as AUC(insulin)) decreased (P = 0.004) in the rosiglitazone group (ROSI group). M value improved in the ROSI group from 33.4 +/- 3.27 to 40.0 +/- 5.51 micromol/kg min (P = 0.04). CONCLUSION Rosiglitazone, by improving menstrual cyclicity, hyperandrogenism, insulin resistance and hyperinsulinaemia, represents an alternative treatment for overweight anovulatory women with PCOS and no pregnancy desire.
Collapse
Affiliation(s)
- K Rautio
- Department of Obstetrics and Gynaecology, Oulu University Hospital, Oulu, Finland
| | | | | | | |
Collapse
|
28
|
Mörsky P, Tiikkainen U, Ruokonen A, Markkanen H. Problematic determination of serum growth hormone: experience from external quality assurance surveys 1998-2003. Scand J Clin Lab Invest 2005; 65:377-86. [PMID: 16081360 DOI: 10.1080/00365510510025791] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Abstract
The objective of the present study was to start a new external quality assurance survey (EQAS) for the determination of serum growth hormone (GH) using pooled serum specimens as quality-assurance samples. To give good coverage of multiple forms of GH, the specimens included sera from GH-deficient and acromegalic patients as well as from persons showing a normal response in GH provocation tests. In one survey the quality-control specimens were spiked with exogenous 22-kD GH to obtain some idea of the specificity and GH recovery of the assays. The EQA surveys of 1998-2003 were organized by Labquality of Helsinki in cooperation with three university hospital laboratories in Finland. The number of participating laboratories ranged from 8 to 14. During 1998-2003, gratifying methodological harmonization occurred in the participating group, as the participants switched to the immunometric detection principle, the number of method applications decreasing from 7 to 3. In 1998 the 14 participating laboratories reported five different conversion factors (from microg/l to mU/l), whereas in 2003 7 of the 8 participants reported the same factor. Despite the harmonization trend among participating laboratories, further efforts are needed, because marked method-based differences still exist. This dialogue should include kit manufacturers, laboratory experts, EQA organizations and clinicians using the test results.
Collapse
Affiliation(s)
- P Mörsky
- Centre for Laboratory Medicine, Pirkanmaa Hospital District, Tampere, Finland.
| | | | | | | |
Collapse
|
29
|
Bennett A, Sovio U, Ruokonen A, Martikainen H, Pouta A, Taponen S, Hartikainen AL, Franks S, Peltonen L, Elliott P, Järvelin MR, McCarthy MI. No association between insulin gene variation and adult metabolic phenotypes in a large Finnish birth cohort. Diabetologia 2005; 48:886-91. [PMID: 15834700 DOI: 10.1007/s00125-005-1737-z] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/28/2004] [Accepted: 12/30/2004] [Indexed: 10/25/2022]
Abstract
AIMS/HYPOTHESIS Although the variable number tandem repeat (VNTR) minisatellite 5' to the insulin gene is among the most studied polymorphisms in diabetes, the relationships between VNTR variation, diabetes-related traits and predisposition to type 2 diabetes remain unclear. Since inadequate sample size is likely to have been an obstacle to reliable inference, we examined the relationship between VNTR variation and a range of diabetes-related traits in a cohort of 5,753 Finnish adults. MATERIALS AND METHODS VNTR genotypes were derived, by typing at the -23HphI variant site, for 5,646 individuals from the Northern Finland Birth Cohort 1966. Associations were sought between these genotypes and a range of anthropometric (BMI, WHR), physiological (blood pressure) and biochemical (fasting glucose, insulin, lipids, indices of insulin sensitivity and beta cell function) measures obtained at clinical examination at 31 years. RESULTS We found no evidence that VNTR genotype was significantly associated with measures of insulin secretion, insulin sensitivity, glycaemia, adiposity or blood pressure. CONCLUSIONS/INTERPRETATION Despite evidence from several relatively small studies suggesting that INS-VNTR genotypes are associated with predisposition to type 2 diabetes, reduced beta cell function and measures of adiposity, the present study failed to detect any association with a range of diabetes-related traits. Taken with other recent studies in large population-based cohorts, these data suggest that previous studies have, at the very least, overestimated the influence of the INS-VNTR on type 2 diabetes-related traits. The effects of INS-VNTR variation on insulin transcription observed in vitro appear not to translate into detectable differences in basal insulin secretion in humans.
Collapse
Affiliation(s)
- A Bennett
- Oxford Centre for Diabetes, Endocrinology and Metabolism, Churchill Hospital Site, Old Road, Headington, Oxford OX3 7LJ, UK
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Rautio K, Tapanainen JS, Ruokonen A, Morin-Papunen LC. Effects of metformin and ethinyl estradiol-cyproterone acetate on lipid levels in obese and non-obese women with polycystic ovary syndrome. Eur J Endocrinol 2005; 152:269-75. [PMID: 15745936 DOI: 10.1530/eje.1.01840] [Citation(s) in RCA: 56] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
OBJECTIVE Women with polycystic ovary syndrome (PCOS) exhibit risk factors for cardiovascular diseases such as abdominal obesity, insulin resistance and dyslipidemia. Insulin sensitizers, especially metformin, have been shown to improve these metabolic disturbances, but there are only a few studies on their effects on serum lipids in polycystic ovary syndrome. METHODS Thirty-five women with PCOS (18 obese and 17 non-obese) were randomized to 6-month treatments with metformin or ethinyl estradiol-cyproterone acetate oral contraceptive pills. RESULTS In the whole-study population (non-obese and obese women) serum levels of high-density lipoprotein cholesterol increased from 1.4+/-0.2 to 1.6+/-0.1 mmol/l (means +/-S.E. throughout) at 3 and 6 months (P < 0.001), the total cholesterol:high-density lipoprotein cholesterol ratio decreased significantly from 3.8+/-0.3 to 3.3+/-0.2 at 6 months (P < 0.001) and a similar trend was observed in serum triglyceride levels during metformin treatment. In the oral contraceptive group, serum levels of total cholesterol increased from 4.9+/-0.3 to 5.4+/-0.3 mmol/l (P < 0.05), high-density lipoprotein cholesterol increased from 1.2+/-0.1 to 1.5+/-0.1 mmol/l (P < 0.001), the total cholesterol:high-density lipoprotein cholesterol ratio decreased from 4.6+/-0.4 to 3.7+/-0.2 (P < 0.001) and triglycerides increased from 1.3+/-0.1 to 1.9+/-0.2 mmol/l at 6 months of treatment (P < 0.001). Serum low-density lipoprotein cholesterol levels remained unchanged during both treatments. Milder but similar changes in the subgroups of obese and non-obese women were observed during both treatments. Moreover, in the whole-study population both systolic (P = 0.02) and diastolic (P = 0.05) blood pressures decreased over the 6 months of metformin treatment. CONCLUSION In women with PCOS, metformin treatment had beneficial effects on lipid profile and blood pressure, and therefore it could be useful in the prevention of cardiovascular complications in these women.
Collapse
Affiliation(s)
- K Rautio
- Department of Obstetrics and Gynecology, University Hospital of Oulu, PO Box 5000, FIN-90 014, Finland
| | | | | | | |
Collapse
|
31
|
Morin-Papunen LC, Vauhkonen I, Ruokonen A, Tapanainen JS, Raudaskoski T. Effects of tibolone and cyclic hormone replacement therapy on glucose metabolism in non-diabetic obese postmenopausal women: a randomized study. Eur J Endocrinol 2004; 150:705-14. [PMID: 15132728 DOI: 10.1530/eje.0.1500705] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
OBJECTIVE AND METHODS To study the effects of hormone replacement therapy on glucose metabolism, 31 obese (body mass index > or =27 kg/m(2)) postmenopausal women were randomized to treatment with tibolone (2.5 mg once daily; TIB; n=16) or to oestradiol valerate (2 mg daily)-dydrogesterone (20 mg daily for 2 weeks every 3 months; ED; n=15) for 12 months. Oral (OGTTs) and intravenous glucose tolerance tests (IVGTTs) and a euglycaemic hyperinsulinaemic clamp were performed before and at 6 and 12 months of treatment. RESULTS TIB decreased the rates of whole body glucose uptake (WBGU) at 6 (P=0.04) and 12 months (P<0.001), but it did not have a significant effect on glucose tolerance. In OGTTs, serum insulin and C-peptide concentrations 2 h after the oral glucose load were increased (P<0.001 and P=0.05 respectively) at 12 months of treatment with TIB, but no changes in the areas under the curve (AUC) of insulin or C-peptide were observed. Furthermore, TIB did not have a significant effect on insulin secretion, the metabolic clearance rate (MCR) of insulin or hepatic insulin extraction. Treatment with ED did not modify the rates of WBGU, but it increased the MCR of insulin (P=0.017) and hepatic insulin extraction (P<0.001) and tended to decrease the insulin AUC (P=0.07). Moreover, glucose tolerance slightly deteriorated during this treatment (P=0.02). Although early phase insulin secretion evaluated by the serum C-peptide response at 30 min in the OGTT increased (P=0.046), the first-phase insulin response during the IVGTT decreased (P=0.05) during ED treatment. CONCLUSIONS Despite the impairment in peripheral insulin sensitivity, TIB treatment had a neutral effect on glucose tolerance, possibly due to a compensatory decrease in endogenous glucose production. The increased demand on insulin induced by ED, due to both a stimulatory effect on pancreatic beta cells and increased insulin metabolism, may explain the slightly detrimental effect on glucose tolerance with this treatment.
Collapse
Affiliation(s)
- L C Morin-Papunen
- Department of Obstetrics and Gynecology, University Hospital of Oulu, FIN-90014 University of Oulu, Oulu, Finland
| | | | | | | | | |
Collapse
|
32
|
Taponen S, Ahonkallio S, Martikainen H, Koivunen R, Ruokonen A, Sovio U, Hartikainen AL, Pouta A, Laitinen J, King V, Franks S, McCarthy MI, Järvelin MR. Prevalence of polycystic ovaries in women with self-reported symptoms of oligomenorrhoea and/or hirsutism: Northern Finland Birth Cohort 1966 Study. Hum Reprod 2004; 19:1083-8. [PMID: 15044401 DOI: 10.1093/humrep/deh214] [Citation(s) in RCA: 64] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND The aim of this study was to investigate the prevalence of polycystic ovaries (PCO) among women with self-reported oligomenorrhoea and/or hirsutism and to see whether women with symptoms and PCO have less favourable levels of biochemical markers than controls or women with symptoms and normal ovaries. METHODS The ultrasonographic ovarian morphology and the hormonal and metabolic profile of female cases with self-reported symptoms typical of polycystic ovary syndrome (PCOS) (n = 196) and asymptomatic controls (n = 67) at the age of 31 years were examined in a general population-based Northern Finland Birth Cohort 1966. RESULTS The prevalence of PCO (37.3 versus 18.2%; P = 0.004) was significantly higher in the cases (oligomenorrhoea and/or hirsutism) than in the controls. PCO morphology was detected in 18.4% of those who reported only hirsutism, in 47.9% of those reporting only oligomenorrhoea, and in 70.4% of those reporting both symptoms. In the cases with PCO compared to (i) the controls and (ii) the cases without PCO, body mass index (P = 0.026 and P = 0.011), ovarian volume [right P = 0.001, left P = 0.208 (non-significant) and right P < 0.001, left P = 0.022], mean follicle number (P < 0.001 and P < 0.001), testosterone (P = 0.063 and P = 0.029), free androgen index (P = 0.007 and P = 0.013) and insulin (P = 0.033 and P = 0.040) were higher, and sex hormone-binding globulin (P = 0.039 and P = 0.068) and glucose:insulin ratio (P = 0.060 and P = 0.054) lower. Cases with PCO also had higher waist:hip ratio (P = 0.011), infertility rate (P = 0.005) and glucose (P = 0.045) and lower insulin-like growth factor-binding protein-1 (P = 0.012) than controls. The clinical, hormonal and metabolic characteristics did not differ significantly between cases without PCO and controls with the exception of infertility rate, which was significantly higher in the cases without PCO (26.4 vs. 10.0%; P = 0.009). CONCLUSIONS In a general population, women with symptoms of oligomenorrhoea and/or hirsutism more often have PCO than asymptomatic women. Levels of biochemical and clinical markers in symptomatic women with PCO differed from and were less favourable than those in symptomatic women without PCO or asymptomatic women, implying an increased risk for health.
Collapse
Affiliation(s)
- S Taponen
- Department of Clinical Chemistry, University of Oulu and Oulu University Hospital, Finland.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Laitinen J, Taponen S, Martikainen H, Pouta A, Millwood I, Hartikainen AL, Ruokonen A, Sovio U, McCarthy MI, Franks S, Järvelin MR. Body size from birth to adulthood as a predictor of self-reported polycystic ovary syndrome symptoms. Int J Obes (Lond) 2003; 27:710-5. [PMID: 12833115 DOI: 10.1038/sj.ijo.0802301] [Citation(s) in RCA: 119] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
OBJECTIVE To study the association between body size from birth to adulthood and self-reported symptoms of polycystic ovary syndrome (PCOS), particularly hirsutism and menstrual disturbances. DESIGN Longitudinal, population-based study of a cohort of women born in 1966 in northern Finland. The study population included 2007 women who were not pregnant and did not use hormonal contraception. Of these 528 (26%) had self-reported symptoms of PCOS. RESULTS Weight at birth, gestational age, being small for gestational age or growth retardation at birth were not associated with PCOS symptoms at 31 y. An increased risk of PCOS symptoms was observed among women with abdominal obesity (waist/hip ratio >85th percentile) at 31 y who had normal weight in adolescence and were overweight (body mass index (BMI) 25.0-29.9 kg/m(2)) or obese (BMI>30.0 kg/m(2)) at 31 y (relative risk (RR) (95% CI) 1.44(1.10-1.89)), and among women with abdominal obesity who were overweight or obese at both 14 and 31 y (1.71 (1.30-2.24)). A total of 30% and 41% of the women with PCOS symptoms in these groups could be attributed, respectively, to overweight, obesity and abdominal obesity at 31 y. CONCLUSIONS These results suggest that obesity in adolescence and in adulthood, and also weight gain after adolescence, particularly in the presence of abdominal obesity, are associated with self-reported PCOS symptoms in adulthood. Thus, based on the results from intervention studies treating PCOS and the results of this study, the prevention of obesity and abdominal obesity is important among young women.
Collapse
Affiliation(s)
- J Laitinen
- Oulu Regional Institute of Occupational Health, Oulu, Aapistie 1, Oulu, Finland.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Perheentupa A, Ruokonen A, Tuomivaara L, Ryynänen M, Martikainen H. Maternal serum beta-HCG and alpha-fetoprotein concentrations in singleton pregnancies following assisted reproduction. Hum Reprod 2002; 17:794-7. [PMID: 11870138 DOI: 10.1093/humrep/17.3.794] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND The reason for the elevated levels of HCG in assisted reproduction pregnancies remains unknown. Our hypothesis was that this increase is caused by the ovarian superovulation therapy. METHODS We compared the beta-HCG and alpha-fetoprotein (AFP) multiples of the median (MoM) in singleton pregnancies after IVF or ICSI with those achieved by frozen embryo transfer (FET) in spontaneous cycles. RESULTS The HCG and AFP MoMs (plus minus SEMs) of 59 FET pregnancies were compared with 144 IVF (including 48 ICSI) pregnancies. The maternal HCG of pregnancies following ovarian stimulation was 1.31 plus minus 0.08 MoM compared with 1.35 plus minus 0.12 MoM in the unstimulated ones. The values for AFP were 1.06 plus minus 0.05 versus 1.11 plus minus 0.05 respectively. No significant differences could be observed between pregnancies following stimulated IVF/ICSI and unstimulated FET cycles. CONCLUSIONS Our results show that second trimester maternal serum HCG is also elevated in singleton pregnancies following spontaneous FET cycles. The increased maternal serum HCG in IVF pregnancies is thus not related to superovulation therapy. Because of the elevated maternal serum HCG levels, serum screening cannot be performed reliably in pregnancies following assisted reproduction technology. Ultrasonographic detection of the nuchal translucency is unaffected and should be used for this group of women undergoing assisted reproduction.
Collapse
Affiliation(s)
- A Perheentupa
- Department of Obstetrics and Gynecology, Department of Clinical Chemistry, P.O. Box 5000, SF-90014, University of Oulu, Finland.
| | | | | | | | | |
Collapse
|
35
|
Piltonen T, Koivunen R, Morin-Papunen L, Ruokonen A, Huhtaniemi IT, Tapanainen JS. Ovarian and adrenal steroid production: regulatory role of LH/HCG. Hum Reprod 2002; 17:620-4. [PMID: 11870113 DOI: 10.1093/humrep/17.3.620] [Citation(s) in RCA: 42] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
BACKGROUND The contribution of the adrenal glands to the total circulating steroid pool in women is not well known. There is evidence that human adrenals express the LH receptor gene and that LH may affect adrenal androgen secretion. METHODS HCG stimulation tests (a single dose of 5000 IU i.m.) were performed in women at reproductive age (group 1, n = 6, age 21--39 years) before and after treatment with a GnRH agonist for 3 weeks, and in oophorectomized post-menopausal women (group 2, n = 6, 47--59 years) during and after estrogen replacement therapy (ERT). RESULTS HCG did not stimulate the secretion of cortisol, dehydroepiandrosterone (DHEA) and dehydroepiandrosterone sulphate (DHEAS) in group 2. In contrast, in group 1, the basal concentrations of serum 17-hydroxyprogesterone (17-OHP), androstenedione, testosterone and estradiol (E(2)) were stimulated significantly (17-OHP 105%, androstenedione 31%, testosterone 20%, E(2) 136%) by HCG, and the treatment with GnRH agonist decreased the responses. The basal serum concentrations of these steroids were significantly lower in oophorectomized women (17-OHP 57%, androstenedione 46%, testosterone 25%), and HCG did not increase these levels. It can be approximated that the ovarian contribution to the circulating levels of 17-OHP, androstenedione and testosterone is 25--30%, and that the adrenals are the primary source of cortisol, DHEA and DHEAS. CONCLUSION LH/HCG does not have a major role in the regulation of adrenal steroid synthesis in endocrinologically healthy women.
Collapse
Affiliation(s)
- T Piltonen
- Department of Obstetrics and Gynaecology, Oulu University Hospital, P.O. Box 5000, FIN-90014 University of Oulu, Finland
| | | | | | | | | | | |
Collapse
|
36
|
Abstract
BACKGROUND Infants of diabetic mothers have been characterized by macrosomia due to hyperinsulinism. A relation has been observed between circulating levels of leptin and the intrauterine growth pattern. METHODS We studied the leptin and insulin concentrations in the cord blood of 29 newborn infants of mothers with type 1 diabetes (iT1DM), 70 newborn infants of mothers with gestational diabetes and 105 newborn infants of nondiabetic mothers. RESULTS There were significant differences (p < 0.001) between the 3 groups with the highest leptin levels 24.9 microg/l (range 1.7-94.1) in infants of mothers with iT1DM and the second-highest levels 14.0 microg/l (range 2.6-74.9) in infants of mothers with gestational diabetes (iGDM), whereas the control infants had the lowest leptin levels 10.0 microg/l (range 0.10-45.9). Girls had higher leptin concentrations than boys among the iT1DM and control infants. The insulin concentrations were 18.1 mU/l (range 1.9-123.3), 6.1 mU/l (range 1.1-51.4) and 3.6 mU/l (range 0.5-21.5) in the 3 groups (p < 0.001), respectively. A significant correlation was observed between leptin and insulin concentrations in iGDM and control infants (r = 0.51; p < 0.001 and r = 0.25; p < 0.05). Both absolute and relative birth weights correlated with leptin levels in all 3 groups (r = 0.60, p = 0.01 and r = 0.51, p = 0.05 in iT1DM; r = 0.51 and 0.56, p < 0.001 in iGDM and r = 0.42 and 0.59, p < 0.001 in control infants). CONCLUSION Our results confirm the relation between leptin concentrations and birth weight. They also suggest that leptin may be involved in the increased accumulation of adipose tissue characteristic of infants of diabetic mothers.
Collapse
Affiliation(s)
- P Tapanainen
- Department of Pediatrics, University of Oulu, FIN-90230 Oulu, Finland.
| | | | | | | |
Collapse
|
37
|
Koivunen RM, Morin-Papunen LC, Ruokonen A, Tapanainen JS, Martikainen HK. Ovarian steroidogenic response to human chorionic gonadotrophin in obese women with polycystic ovary syndrome: effect of metformin. Hum Reprod 2001; 16:2546-51. [PMID: 11726572 DOI: 10.1093/humrep/16.12.2546] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND The aim of the present study was to investigate the steroidogenic response pattern to HCG in obese women with polycystic ovary syndrome (PCOS) and the possible effects of metformin treatment on it. METHODS A single injection of human chorionic gonadotrophin (HCG, 5000 IU) was given to 12 obese [body mass index (BMI) > or = 27 kg/m2] women with PCOS and to 27 control women. Blood samples for assays of 17alpha-hydroxyprogesterone (17-OHP), androstenedione, testosterone and oestradiol were collected at baseline and 1, 2 and 4 days after the injection. Responses to HCG were also assessed in the PCOS women after 2-month treatment with metformin (500 mg x 3 daily). RESULTS Serum 17-OHP and oestradiol concentrations peaked at 24 h in the PCOS women and preceded the maximum testosterone concentration, which was seen at 48 h. In the control women the maximum concentrations of all these steroids were reached 96 h after HCG. After metformin treatment, the basal serum testosterone concentration and the areas under the androstenedione (AUC(A)) and testosterone (AUC(T)) response curves after HCG decreased significantly. CONCLUSIONS The results demonstrate that obese PCOS women have a male-type steroidogenic response pattern to a single injection of HCG and a higher androgen secretory capacity than control women, which may be explained by the increased thecal cell activity in the polycystic ovary. The slight alleviation of hyperandrogenism brought about by metformin therapy appears to be due to its effect on ovarian steroidogenesis possibly mediated by decreased insulin action.
Collapse
Affiliation(s)
- R M Koivunen
- Department of Obstetrics and Gynaecology, University Hospital of Oulu, Kajaanintie 52A, FIN-90220 Oulu, Finland
| | | | | | | | | |
Collapse
|
38
|
Kurkinen-Räty M, Ruokonen A, Vuopala S, Koskela M, Rutanen EM, Kärkkäinen T, Jouppila P. Combination of cervical interleukin-6 and -8, phosphorylated insulin-like growth factor-binding protein-1 and transvaginal cervical ultrasonography in assessment of the risk of preterm birth. BJOG 2001; 108:875-81. [PMID: 11510716 DOI: 10.1111/j.1471-0528.2001.00199.x] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Abstract
OBJECTIVE To determine the value of combinations of cervical interleukin-6 (IL-6), cervical interleukin-8 (IL-8), the phosphorylated isoform of insulin-like growth-factor binding protein-1 (IGFBP-1), and cervical ultrasonography in the prediction of preterm birth. DESIGN Prospective follow up. SETTING Oulu University Hospital maternity clinic from February 1997 to July 1998. POPULATION Women with singleton pregnancies (n = 77), referred from outpatient clinics at 22-32 weeks of gestation with symptoms (uterine contractions) or signs (cervical change) of threatened preterm birth. Symptomless women (n = 78) matched for gestational age, parity and maternal age at recruitment were studied as a reference group. METHODS A urine sample for bacterial culture was collected, and cervical swab samples for assays of interleukin-6 and -8 and phoshorylated IGFBP-1 were taken before digital cervical examination. A Pap smear for analysis of bacterial vaginosis and samples for analysis of chlamydia and streptococci were also obtained. Cervical measurements were made by transvaginal ultrasonography. The same sampling and cervical measurement were repeated twice at two-week intervals. The cutoff values of the markers were determined by receiver-operating characteristic curve analysis. MAIN OUTCOME MEASURE Preterm birth (<37 weeks). RESULTS The preterm birth (<37 weeks) rate for women in the study group was 16% (12/77). The cervical interleukin-6 cutoff value (61 ng/L) at first visit had a sensitivity of 73% and a specificity of 61% in predicting preterm birth, with a positive likelihood ratio (LR+ ) of 1.9 (95% CI 1.2-3.0). An ultrasonographically measured cervical index value of > 0.36 at recruitment predicted preterm birth in 25% (5/20) of the study group compared with 9% (5/54); LR+ 2.2 (95% CI 1.03-4.7). Cervical phosphorylated IGFBP-1 > 6.4 microg/L [LR+ 1.8 (95% CI 0.7-2.9)], interleukin-8 > 3739 ng/L [LR+ 1.4 (95% CI 0.9-2.4)], and ultrasonograpic cervical length < 29.3 mm [LR+ 2.7 (95% CI 0.8-9.7)] increased the risk of preterm birth. According to the logistic regression model, a combination of IL-6, and IL-8 and cervical index increased the specificity to 97%, but the sensitivity fell to 30% in detecting preterm birth. There was a significantly increased incidence of puerperal infections if phosphorylated IGFBP-1 concentrations were elevated (> 21.0 microg/L), 36% (4/11) compared with 4.6% (3/65), LR+ 6.7 (95% CI 2.7-17), the sensitivity being 67% (4/6) and the specificity 90% (63/70). Elevated phosphorylated IGFBP-1 concentrations (> 21.6 microg/L) were also associated with an increased risk of neonatal infections; LR+ 8.0 (95% CI 3.5-18). CONCLUSIONS An increase in cervical IL-6 concentration and the ultrasonographically measured cervical index appear to be associated with preterm birth. A combination of these markers with measurement of cervical IL-8 appears to be the best predictor of preterm birth. Neither the sensitivity nor specificity of the tests used in this study are good enough to predict preterm birth for clinical decision making. Cervical phosphorylated IGFBP-1 seems to be a marker of puerperal and neonatal infectious morbidity in cases of threatened preterm delivery, suggesting early tissue degradation at the choriodecidual interface.
Collapse
Affiliation(s)
- M Kurkinen-Räty
- Department of Obstetrics and Gynaecology, University of Oulu, Finland
| | | | | | | | | | | | | |
Collapse
|
39
|
Abstract
BACKGROUND Granulosa cell tumors are known to be hormonally active. They usually produce estrogen and inhibin, and the serum inhibin level is often considered a useful tumor marker during the follow-up of this illness. CASE We present a case of malignant juvenile granulosa cell tumor associated with hyperprolactinemia. In our patient, the serum prolactin concentration closely reflected the behavior of the disease. CONCLUSION Our findings are consistent with the assumption that prolactin was a tumor marker in this patient.
Collapse
Affiliation(s)
- M Santala
- Department of Obstetrics and Gynecology, University Hospital of Oulu, FIN-90220, Oulu, Finland.
| | | | | | | | | |
Collapse
|
40
|
Koivunen RM, Juutinen J, Vauhkonen I, Morin-Papunen LC, Ruokonen A, Tapanainen JS. Metabolic and steroidogenic alterations related to increased frequency of polycystic ovaries in women with a history of gestational diabetes. J Clin Endocrinol Metab 2001; 86:2591-9. [PMID: 11397859 DOI: 10.1210/jcem.86.6.7612] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
The prevalence of polycystic ovaries (PCO) and clinical, endocrine, and metabolic features were investigated in women with previous gestational diabetes (GDM). Thirty-three women with a history of GDM and 48 controls were studied. Glucose and insulin secretion capacity was evaluated by means of the oral glucose tolerance test (OGTT), and insulin action was determined by means of a euglycemic insulin clamp. Compared with control women, women with previous GDM more often had significantly abnormal OGTT, a higher prevalence of PCO (39.4% vs. 16.7%; P = 0.03), higher serum concentrations of cortisol, dehydroepiandrosterone, and dehydroepiandrosterone sulfate and a greater area under the glucose curve. Women with previous GDM showed a lowered early phase insulin response to glucose and impaired insulin sensitivity, which was accounted for mainly by decreased glucose nonoxidation. They also demonstrated a significantly lower fasting serum C peptide/insulin ratio than the controls, indicating that women with previous GDM have impaired hepatic insulin extraction, which tended to be more marked among women with PCO. This may explain why women with PCO and previous GDM were significantly more hyperinsulinemic than women with normal ovaries. In conclusion, our data demonstrate that women with previous GDM often have PCO and abnormal OGTT. They are insulin resistant as a result of lowered glucose nonoxidation and show inappropriately low insulin responses to glucose, reflecting impaired beta-cell function. They also have higher adrenal androgen secretion, which may be associated with abdominal obesity.
Collapse
Affiliation(s)
- R M Koivunen
- Departments of Obstetrics and Gynecology (R.M.K., J.J., L.C.M.-P., J.S.T.) and Clinical Chemistry (A.R.), University Hospital of Oulu, 90220 Oulu
| | | | | | | | | | | |
Collapse
|
41
|
Niemimaa M, Suonpää M, Perheentupa A, Seppälä M, Heinonen S, Laitinen P, Ruokonen A, Ryynänen M. Evaluation of first trimester maternal serum and ultrasound screening for Down's syndrome in Eastern and Northern Finland. Eur J Hum Genet 2001; 9:404-8. [PMID: 11436120 DOI: 10.1038/sj.ejhg.5200655] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2000] [Revised: 03/18/2001] [Accepted: 03/20/2001] [Indexed: 11/09/2022] Open
Abstract
The current trend in prenatal diagnosis is that trisomy screening is being moved to the first trimester and ultrasonographic nuchal translucency measurement is included in risk calculation. It is likely that biochemical screening in the second trimester will gradually be given up. In Eastern and Northern Finland, during the year 1999 we offered first-trimester ultrasonographic and serum screening for trisomy 21, with measurements of maternal serum PAPP-A and beta-hCG. A total of 2515 pregnant women participated in the screening, yielding the detection of eight foetuses with Down's syndrome. Six affected foetuses (75%) were detected by means of first-trimester serum screening. Since we were in the phase of collecting data for the Finnish medians for PAPP-A and beta-hCG, the women were not given the estimates of risk for trisomy 21. Only 1602 of the 2515 enrolled women had the combination of first-trimester ultrasonographic and serum screening performed, and in that group there were five foetuses with Down's syndrome. The combination ultrasonographic and serum approach yielded a Down's syndrome detection rate of 80% (four out of five) with a 5% false positive rate, whereas in nuchal translucency based-screening the detection rate was 60%, with a 5% false positive rate.
Collapse
Affiliation(s)
- M Niemimaa
- Department of Obstetrics and Gynaecology, Oulu University Hospital, Oulo, Finland
| | | | | | | | | | | | | | | |
Collapse
|
42
|
Abstract
In order to evaluate the effects of climatic factors on the secretion of thyroid hormones and TSH in a high latitude population, we have taken serum and urine samples from 20 healthy men from northern Finland (67 degrees -68 degrees N) every 2 months for a period of 14 months. Serum free triiodothyronine (T(3)) levels were lower in February than in August (3.9 vs 4.4 pmol/l, P<0.05) and TSH levels were higher in December than during other months (2.1 vs 1.5-1.7 mU/l, P<0.01). Serum total and free thyroxine (T(4)), total T(3) and reverse T(3) levels and urinary T(4) levels were unchanged. Urinary T(3) levels were significantly higher in winter than in summer. Serum free T(3) correlated highly significantly with the outdoor temperature integrated backwards weekly for 7-56 days (r=0.26 for 1-56 days) from the day when the blood samples were taken. Serum TSH did not show any significant correlation with the thyroid hormones or with the integrated temperature of the previous days, but it did show an inverse and significant correlation (r=-0.31) with the ambient luminosity integrated backwards for 7 days from the day when the blood sample was taken. The gradually increasing correlation between outdoor temperatures and serum free T(3) suggests that the disposal of thyroid hormones is accelerated in winter, leading to low serum free T(3) levels and a high urinary free T(3) excretion. Since there was no correlation between thyroid hormones and serum TSH, the feedback mechanism between TSH and thyroid hormones may not be the only contributing factor, and other factors such as ambient luminosity may at least partly determine serum TSH in these conditions. Also urinary free T(3) appears to be a novel and non-invasive indicator for thyroid physiology.
Collapse
Affiliation(s)
- J Hassi
- Oulu Regional Institute of Occupational Health, Oulu, Finland
| | | | | | | |
Collapse
|
43
|
Morin-Papunen LC, Vauhkonen I, Koivunen RM, Ruokonen A, Martikainen HK, Tapanainen JS. Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study. J Clin Endocrinol Metab 2000; 85:3161-8. [PMID: 10999803 DOI: 10.1210/jcem.85.9.6792] [Citation(s) in RCA: 36] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
Metformin, a biguanide antihyperglycemic drug, has been shown to improve ovarian function and glucose metabolism in women with polycystic ovary syndrome (PCOS), but results concerning its effects on insulin sensitivity are controversial. Oral contraceptive pills are commonly used in the treatment of PCOS; but, like metformin, their influence on insulin sensitivity is not well known. We randomized 32 obese (body mass index > 27 kg/m2) women with PCOS, either to metformin (500 mg x 2 daily for 3 months, then 1,000 mg x 2 daily for 3 months) or to ethinyl estradiol (35 microg)-cyproterone acetate (2 mg) oral contraceptive pills (Diane Nova) for 6 months. Metformin significantly decreased the waist-to-hip ratio, serum testosterone, fasting free fatty acid, and insulin concentrations and improved oxidative glucose utilization and menstrual cyclicity, with slight (but nonsignificant) improvements in insulin hepatic extraction and insulin sensitivity. Diane Nova significantly decreased serum testosterone and increased serum sex hormone-binding globulin concentrations and glucose area under the curve during oral glucose tolerance test. It is concluded that metformin, probably by way of its effect on adipose tissue, leads to reduction of hyperinsulinemia and concomitant improvement in the menstrual pattern; and therefore, it offers a useful alternative treatment for obese, anovulatory women with PCOS. Despite slight worsening of glucose tolerance, Diane Nova is an efficient treatment for women with hyperandrogenism and hirsutism.
Collapse
Affiliation(s)
- L C Morin-Papunen
- Department of Obstetrics and Gynecology, University Hospital of Oulu, Finland
| | | | | | | | | | | |
Collapse
|
44
|
Morin-Papunen LC, Vauhkonen I, Koivunen RM, Ruokonen A, Tapanainen JS. Insulin sensitivity, insulin secretion, and metabolic and hormonal parameters in healthy women and women with polycystic ovarian syndrome. Hum Reprod 2000; 15:1266-74. [PMID: 10831553 DOI: 10.1093/humrep/15.6.1266] [Citation(s) in RCA: 139] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
To study the contributions of body mass, body fat distribution and family history of type 2 diabetes mellitus to hyperinsulinaemia, insulin secretion and resistance in polycystic ovarian syndrome (PCOS), 17 lean (LC) and 17 obese (OC) healthy control subjects, and 15 lean (LPCOS) and 28 obese (OPCOS) women with PCOS were investigated. Waist:hip ratio (WHR), serum concentrations of sex steroids, glucose and insulin during a 75 g oral glucose tolerance test (OGTT), and insulin and C-peptide early phase secretion, and insulin sensitivity index using a euglycaemic hyperinsulinaemic clamp were assessed. The PCOS subjects had a higher mean WHR than the controls. A trend towards hyperinsulinaemia and impairment of insulin sensitivity (including the rates of both glucose oxidation and non-oxidation) was observed in LPCOS subjects, but only in OPCOS subjects were these changes significant. Early phase insulin secretion but not the early phase C-peptide secretion was increased in PCOS subjects compared to controls, suggesting that peripheral hyperinsulinaemia in PCOS women was mainly due to the observed lowered hepatic insulin extraction and insulin resistance in skeletal muscle. Moreover, the presence of a family history of type 2 diabetes did not affect early phase insulin or C-peptide secretion in the PCOS group. These results confirm and strengthen earlier contentions, that insulin resistance is a characteristic defect in PCOS and is worsened particularly by abdominal obesity.
Collapse
Affiliation(s)
- L C Morin-Papunen
- Department of Obstetrics and Gynecology, University Hospital of Oulu, Finland
| | | | | | | | | |
Collapse
|
45
|
Vierimaa H, Timisjärvi J, Eloranta E, Saarela S, Ruokonen A, Leppäluoto J. Effects of seasonal photoperiod on serum 25-hydroxycholecalciferol and calcium in reindeer, Rangifer tarandus tarandus. Int J Circumpolar Health 2000; 59:33-7. [PMID: 10850005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/16/2023] Open
Abstract
In order to understand the effects of solar irradiance on calcium metabolism we measured serum 25-hydroxycholecalciferol and total calcium levels monthly in 6 female nonpregnant reindeer maintained in the Oulu area (65 degrees N). Mean monthly serum total calcium levels varied slightly and the highest levels were seen in October. Serum 25-hydroxycholecalciferol levels were highest in October but the monthly variation was also slight. The small monthly variation of the analytes' abundance and the fact that they peaked not until 4 months after the longest day, (i.e. the main stimulus for vitamin D synthesis) could have something to do with the supplementation of this vitamin in the diet of the captive reindeer.
Collapse
Affiliation(s)
- H Vierimaa
- Department of Physiology, University of Oulu, Finland
| | | | | | | | | | | |
Collapse
|
46
|
Molin-Papunen L, Koivunen R, Vauhkonen I, Ruokonen A, Martikainen H, Tapanainen J. P-252. Endocrine and metabolic effects of metformin and ethinyl oestradiol-cyproterone acetate in obese and lean women with polycystic ovary syndrome: a randomized comparative study. Hum Reprod 1999. [DOI: 10.1093/humrep/14.suppl_3.267] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
47
|
Leino TK, Leppäluoto J, Ruokonen A, Kuronen P. Neuroendocrine responses and psychomotor test results in subjects participating in military pilot selection. Aviat Space Environ Med 1999; 70:571-6. [PMID: 10373048] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
Abstract
BACKGROUND Military flying sets high demands on the mental performance and stress tolerance of pilots. Neuroendocrine responses could be a method for evaluating stress tolerance. METHODS Psychological workload and neuroendocrine responses associated with the psychomotor Wiener's test were studied in 80 male volunteers. These personnel had applied for the basic military flying program of the Finnish Air Force (FAF). After the first blood sample at 0930 h, the subjects were randomly assigned to test (n = 40) and control groups (n = 40). The test group performed the psychomotor test, which lasted 10 min. The second blood sample was collected 1 min after the test. The control group was clinically examined and the blood sample was taken in the same way. RESULTS A high plasma ACTH level before the psychomotor test predicted (r = 0.36, p = 0.02) a poor overall result in the psychomotor test. After the psychomotor test, plasma adrenocorticotropin (ACTH) and beta-endorphin levels were significantly higher than before the test. They were also higher than in the control group. Plasma cortisol and prolactin levels increased after the psychomotor test, but the increase was not statistically significant. High ACTH, cortisol and prolactin increments were specific to a high amount of delayed (over 2 s) psychomotor responses, as a marker of information overload. CONCLUSIONS Elevated plasma ACTH, cortisol and prolactin levels, after the psychomotor test, were associated with a high amount of the delayed responses. This indicates that high neuroendocrine responses were connected with problems in stress tolerance during information processing. High neuroendocrine reactions under information load could, therefore, be used for identification of lowered stress tolerance.
Collapse
Affiliation(s)
- T K Leino
- Department of Physiology, University of Oulu, Finland
| | | | | | | |
Collapse
|
48
|
Leino TK, Leppäluoto J, Ruokonen A, Kuronen P. Neuroendocrine responses to psychological workload of instrument flying in student pilots. Aviat Space Environ Med 1999; 70:565-70. [PMID: 10373047] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
Abstract
BACKGROUND Information processing and stress tolerance are necessary features for instrument flying (IFR), especially among student pilots. Psychological workload of IFR flight may lead to stress reactions such as neuroendocrine activity. METHODS Neuroendocrine responses to an IFR flight with Vinka piston-engined primary trainer were studied in 35 male volunteers who participated in the basic military flying course of the Finnish Air Force (FAF). The student pilots performed a 40-min IFR flight mission and a control session on land in randomized order between 11.00 h and 15.00 h. The IFR flight included 3 NDB approaches and was evaluated by flight instructors. Blood samples were collected 15 min before, 5 min and 60 min after the flight as well as control session, and. Plasma ACTH, beta3-endorphin (BE), cortisol, prolactin, adrenaline (A) and noradrenaline (NA) were measured. Psychological evaluations included psychomotor test (Wiener), Multi Coordination and Attention Test, ability tests and personality tests (CMPS and 16 PF). The overall psychological evaluation was made by an aviation psychologist. RESULTS Plasma ACTH was significantly higher before and 5 min after the flight compared with control levels, but plasma BE increased significantly only before the flight. Plasma cortisol was significantly elevated before and 5 min after the flight. Plasma prolactin, NA and A increases were significant 5 min after the flight. High A levels after the flight correlated significantly with poor IFR flight performance as well as with poor psychomotor test results. CONCLUSIONS The plasma prolactin and NA increases after the flight represented a direct type of stress reaction to the flight situation. The plasma BE response to IFR flight was an anticipatory stress reaction, but plasma ACTH, cortisol and A responses included both anticipatory and direct types of stress reactions. Psychological factors, flight performance and neuroendocrine responses to IFR flight appear to be associated with each other. Therefore, neuroendocrine reactions as a response to the psychological workload of military flying could be used for identifying stress tolerance in military pilots.
Collapse
Affiliation(s)
- T K Leino
- Department of Physiology, University of Oulu, Finland
| | | | | | | |
Collapse
|
49
|
Abstract
The aim of this study was to assess the value of serum inhibin B in detecting male gonadal dysfunction in childhood cancer survivors. 27 male postpubertal (Tanner's pubertal stage G5 or P6) and 12 pubertal (> or = G2) patients were drawn from the endocrine follow-up protocol of childhood cancer patients at the Paediatric Clinic of Turku University Hospital, Turku, Finland. The average time (mean +/- S.D.) between the diagnosis and this study was 11.7 +/- 4.5 years in the postpubertal and 7.0 +/- 3.9 years in the pubertal group. Serum samples for the determination of follicle-stimulating hormone (FSH), luteinising hormone (LH), oestradiol, testosterone, and inhibin A and B dimers were collected. The demographic factors, pubertal stage and testicular size of the patient were measured at the same routine outpatient visit. Serum inhibin concentrations were correlated to testicular volume and gonadotrophin concentrations. Strong correlations were observed between testicular size (r = 0.80, P < 0.001) or FSH (r = -0.58, P = 0.002) and inhibin B concentration in the postpubertal group. Inhibin A was not detectable (< 2 pg/ml). Testicular volume measurement was accurately documented in 21 postpubertal subjects. Patients with small testicles (< 10 ml) had inhibin B concentrations under 42 pg/ml and those whose testicular size was over 13 ml had inhibin B concentrations exceeding 100 pg/ml. In all 12 pubertal survivors, serum inhibin B levels were > or = 94 pg/ml, except in one case of testicular cancer where inhibin B was 8.1 pg/ml and the FSH concentration was elevated. Inhibin B seems to be an indicator of male gonadal function in postpubertal childhood cancer survivors and could be used in the estimation of gonadal function of male survivors earlier than testicular volume or semen analyses would be routinely possible. However, the correct cut-off level of serum inhibin B, as well as the details of inhibin B physiology during puberty, remain to be determined before semen analysis can be replaced by the measurement of inhibin B.
Collapse
|
50
|
Santala M, Burger H, Ruokonen A, Stenbäck F, Kauppila A. Elevated serum inhibin and tumor-associated trypsin inhibitor concentrations in a young woman with dysgerminoma of the ovary. Gynecol Oncol 1998; 71:465-8. [PMID: 9887252 DOI: 10.1006/gyno.1998.5191] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
We describe a patient with dysgerminoma who had elevated serum inhibin, tumor-associated trypsin inhibitor (TATI), and CA 125 concentrations, which increased progressively during follow-up of the advancing disease. Inhibin levels correlated closely with disease behavior. In contrast to inhibin, serum TATI and CA 125 failed to reveal the presence of silent disease.
Collapse
Affiliation(s)
- M Santala
- Department of Obstetrics and Gynecology, University Hospital of Oulu, Oulu, Finland.
| | | | | | | | | |
Collapse
|